US20140311890A1 - Photoacid compounds, and related compositions, methods and systems - Google Patents
Photoacid compounds, and related compositions, methods and systems Download PDFInfo
- Publication number
- US20140311890A1 US20140311890A1 US14/362,887 US201214362887A US2014311890A1 US 20140311890 A1 US20140311890 A1 US 20140311890A1 US 201214362887 A US201214362887 A US 201214362887A US 2014311890 A1 US2014311890 A1 US 2014311890A1
- Authority
- US
- United States
- Prior art keywords
- compound
- moiety
- photoacid
- substituted
- light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 183
- 238000000034 method Methods 0.000 title claims description 51
- 239000000203 mixture Substances 0.000 title description 32
- 238000006243 chemical reaction Methods 0.000 claims abstract description 56
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 30
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 14
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims abstract description 11
- 125000005647 linker group Chemical group 0.000 claims description 65
- 125000003118 aryl group Chemical group 0.000 claims description 49
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- -1 hetroarylamino Chemical group 0.000 claims description 40
- 230000005281 excited state Effects 0.000 claims description 29
- 125000001072 heteroaryl group Chemical group 0.000 claims description 25
- 125000005842 heteroatom Chemical group 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims description 23
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 22
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 22
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 22
- 125000001424 substituent group Chemical group 0.000 claims description 22
- 230000005283 ground state Effects 0.000 claims description 21
- 125000003282 alkyl amino group Chemical group 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 239000001257 hydrogen Substances 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 claims description 12
- 125000004122 cyclic group Chemical group 0.000 claims description 11
- 125000001769 aryl amino group Chemical group 0.000 claims description 10
- 125000004104 aryloxy group Chemical group 0.000 claims description 10
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 125000000743 hydrocarbylene group Chemical group 0.000 claims description 9
- 230000001678 irradiating effect Effects 0.000 claims description 9
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 125000004185 ester group Chemical group 0.000 claims description 3
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 87
- 230000015572 biosynthetic process Effects 0.000 description 49
- 238000003786 synthesis reaction Methods 0.000 description 49
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 36
- 239000000243 solution Substances 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- 0 [1*]C([2*])(CC[4*])OC([3*])=O Chemical compound [1*]C([2*])(CC[4*])OC([3*])=O 0.000 description 22
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 18
- 239000000126 substance Substances 0.000 description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 125000000524 functional group Chemical group 0.000 description 13
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 11
- 150000002390 heteroarenes Chemical group 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000003342 alkenyl group Chemical group 0.000 description 9
- 125000000304 alkynyl group Chemical group 0.000 description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 7
- 125000003710 aryl alkyl group Chemical group 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000002877 alkyl aryl group Chemical group 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 6
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000005284 excitation Effects 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 229960001866 silicon dioxide Drugs 0.000 description 6
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 6
- 125000006686 (C1-C24) alkyl group Chemical group 0.000 description 5
- 229920003026 Acene Polymers 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 229940126540 compound 41 Drugs 0.000 description 5
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 4
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 4
- LCEXZXRIBXVGJD-UHFFFAOYSA-N C1=CC=CC=C1.CC.CC(C)C Chemical compound C1=CC=CC=C1.CC.CC(C)C LCEXZXRIBXVGJD-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 4
- 229960001690 etomidate Drugs 0.000 description 4
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-O hydron;quinoline Chemical compound [NH+]1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-O 0.000 description 4
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 4
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000005588 protonation Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 3
- SYBYTAAJFKOIEJ-UHFFFAOYSA-N 3-Methylbutan-2-one Chemical compound CC(C)C(C)=O SYBYTAAJFKOIEJ-UHFFFAOYSA-N 0.000 description 3
- QCUNDLUTTXSPFM-UHFFFAOYSA-N 3-hydroxynaphthalene-2-carbaldehyde Chemical compound C1=CC=C2C=C(C=O)C(O)=CC2=C1 QCUNDLUTTXSPFM-UHFFFAOYSA-N 0.000 description 3
- MFEILWXBDBCWKF-UHFFFAOYSA-N 3-phenylpropanoyl chloride Chemical compound ClC(=O)CCC1=CC=CC=C1 MFEILWXBDBCWKF-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000000297 Sandmeyer reaction Methods 0.000 description 3
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000002723 alicyclic group Chemical group 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 125000004093 cyano group Chemical group *C#N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 125000001033 ether group Chemical group 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 239000012216 imaging agent Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 150000004291 polyenes Chemical class 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 2
- 229910015845 BBr3 Inorganic materials 0.000 description 2
- WYZIPSHSVPTUND-UHFFFAOYSA-N CC(C)(COc(cc(C(C)(C)C(C)=S1C)c1c1)c1OC(N)=O)OC(N)=O Chemical compound CC(C)(COc(cc(C(C)(C)C(C)=S1C)c1c1)c1OC(N)=O)OC(N)=O WYZIPSHSVPTUND-UHFFFAOYSA-N 0.000 description 2
- ZISSAWUMDACLOM-UHFFFAOYSA-N CC(C)C(C)(C)C Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 2
- WYLLBTPEHIVUKV-UHFFFAOYSA-N CC(C)N(C)C(C)(C)C Chemical compound CC(C)N(C)C(C)(C)C WYLLBTPEHIVUKV-UHFFFAOYSA-N 0.000 description 2
- HNFSPSWQNZVCTB-UHFFFAOYSA-N CC(C)OC(C)(C)C Chemical compound CC(C)OC(C)(C)C HNFSPSWQNZVCTB-UHFFFAOYSA-N 0.000 description 2
- OQDOWNJLYIFTHK-UHFFFAOYSA-N COc1cc2ccccc2cc1C=O Chemical compound COc1cc2ccccc2cc1C=O OQDOWNJLYIFTHK-UHFFFAOYSA-N 0.000 description 2
- 241000694440 Colpidium aqueous Species 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- WQCXXQXGKFLMLP-UHFFFAOYSA-N O=C1Oc2cc(cccc3)c3cc2CC1 Chemical compound O=C1Oc2cc(cccc3)c3cc2CC1 WQCXXQXGKFLMLP-UHFFFAOYSA-N 0.000 description 2
- BERPCVULMUPOER-UHFFFAOYSA-N Quinolinediol Chemical compound C1=CC=C2NC(=O)C(O)=CC2=C1 BERPCVULMUPOER-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- PRJKQKAYRKJOMZ-PABGGZJKSA-N [H]OC1=C(C(C)C)[Y]/C(=C\C=C\C2=NC(C)=C(C)[Y]2)N1 Chemical compound [H]OC1=C(C(C)C)[Y]/C(=C\C=C\C2=NC(C)=C(C)[Y]2)N1 PRJKQKAYRKJOMZ-PABGGZJKSA-N 0.000 description 2
- RHLQUJDEWWLVPJ-UHFFFAOYSA-O [H]OC1=CC2=C(C=C/C(=C\C=C\C3=CC=C4C=CC=CC4=[N+]3C)N2C)C=C1C(C)C Chemical compound [H]OC1=CC2=C(C=C/C(=C\C=C\C3=CC=C4C=CC=CC4=[N+]3C)N2C)C=C1C(C)C RHLQUJDEWWLVPJ-UHFFFAOYSA-O 0.000 description 2
- BVORISOCJPKGQN-JIVDVDSCSA-N [H]OC1=CC2=C(C=C3C=C(/C(C)=C/C=C/C4=C(C)CCCC4(C)C)C=CC3=C2)C=C1C(C)C Chemical compound [H]OC1=CC2=C(C=C3C=C(/C(C)=C/C=C/C4=C(C)CCCC4(C)C)C=CC3=C2)C=C1C(C)C BVORISOCJPKGQN-JIVDVDSCSA-N 0.000 description 2
- ZFLFPZXIMICKGN-UHFFFAOYSA-N [H]OC1=CC2=C(C=C3C=CC=CC3=C2)C=C1C(C)C Chemical compound [H]OC1=CC2=C(C=C3C=CC=CC3=C2)C=C1C(C)C ZFLFPZXIMICKGN-UHFFFAOYSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000006323 alkenyl amino group Chemical group 0.000 description 2
- 125000003302 alkenyloxy group Chemical group 0.000 description 2
- 125000006319 alkynyl amino group Chemical group 0.000 description 2
- 125000005133 alkynyloxy group Chemical group 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 125000005028 dihydroxyaryl group Chemical group 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 150000002596 lactones Chemical class 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229940118019 malondialdehyde Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- NXPPAOGUKPJVDI-UHFFFAOYSA-N naphthalene-1,2-diol Chemical compound C1=CC=CC2=C(O)C(O)=CC=C21 NXPPAOGUKPJVDI-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 1
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 1
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- XXJGBENTLXFVFI-UHFFFAOYSA-N 1-amino-methylene Chemical group N[CH2] XXJGBENTLXFVFI-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-O 1H-indol-1-ium Chemical compound C1=CC=C2[NH2+]C=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-O 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- 150000004786 2-naphthols Chemical class 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- LGDHZCLREKIGKJ-UHFFFAOYSA-N 3,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C=C1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 1
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- CDIIZULDSLKBKV-UHFFFAOYSA-N 4-chlorobutanoyl chloride Chemical compound ClCCCC(Cl)=O CDIIZULDSLKBKV-UHFFFAOYSA-N 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- CLRIMWMVEVYXAK-UHFFFAOYSA-N 5-ethylcyclopenta-1,3-diene Chemical compound CCC1C=CC=C1 CLRIMWMVEVYXAK-UHFFFAOYSA-N 0.000 description 1
- 241001120493 Arene Species 0.000 description 1
- KJQKOARODFFUTM-WJIFESEKSA-R C1=CC=C(/N=C/C/C=N/C2=CC=CC=C2)C=C1.CC(=O)OC(C)=O.CC(=O)OC1=CC=C(Br)C2=C1C(C)(C)C(/C=C/C=C/N(C(C)=O)C1=CC=CC=C1)=[N+]2C.CC1=[N+](C)C2=C(Br)C=CC(O)=C2C1(C)C.CC1=[N+](C)C2=C(Br)C=CC(O)=C2C1(C)C.CC1=[N+](C)C2=CC=CC=C2C1(C)C.CN1C2=C(C(O)=CC=C2Br)C(C)(C)/C1=C\C=C\C=C\C1=[N+](C)C2=C(C(O)=CC=C2Br)C1(C)C.CN1C2=C(C(O)=CC=C2Br)C(C)(C)/C1=C\C=C\C=C\C1=[N+](C)C2=C(C=CC=C2)C1(C)C.Cl Chemical compound C1=CC=C(/N=C/C/C=N/C2=CC=CC=C2)C=C1.CC(=O)OC(C)=O.CC(=O)OC1=CC=C(Br)C2=C1C(C)(C)C(/C=C/C=C/N(C(C)=O)C1=CC=CC=C1)=[N+]2C.CC1=[N+](C)C2=C(Br)C=CC(O)=C2C1(C)C.CC1=[N+](C)C2=C(Br)C=CC(O)=C2C1(C)C.CC1=[N+](C)C2=CC=CC=C2C1(C)C.CN1C2=C(C(O)=CC=C2Br)C(C)(C)/C1=C\C=C\C=C\C1=[N+](C)C2=C(C(O)=CC=C2Br)C1(C)C.CN1C2=C(C(O)=CC=C2Br)C(C)(C)/C1=C\C=C\C=C\C1=[N+](C)C2=C(C=CC=C2)C1(C)C.Cl KJQKOARODFFUTM-WJIFESEKSA-R 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical class C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- MVPUBDZTWXTYQA-UHFFFAOYSA-N C=CC(=O)OCC.O=C1C=CC2=CC3=CC=CC=C3C=C2O1.[H]C(=O)C1=CC2=CC=CC=C2C=C1O Chemical compound C=CC(=O)OCC.O=C1C=CC2=CC3=CC=CC=C3C=C2O1.[H]C(=O)C1=CC2=CC=CC=C2C=C1O MVPUBDZTWXTYQA-UHFFFAOYSA-N 0.000 description 1
- YCRUBTHJONYHIG-UHFFFAOYSA-N CC(=O)C(C)C.COC1=C2C(=C(Br)C=C1)N=C(C)C2(C)C.COC1=CC(N)=C(Br)C=C1 Chemical compound CC(=O)C(C)C.COC1=C2C(=C(Br)C=C1)N=C(C)C2(C)C.COC1=CC(N)=C(Br)C=C1 YCRUBTHJONYHIG-UHFFFAOYSA-N 0.000 description 1
- YMCAIWQFMFRKPU-UHFFFAOYSA-N CC(=O)C(C)C.COC1=CC2=C(C=C1OC)C(C)(C)C(C)=N2.COC1=CC=C(N)C=C1OC Chemical compound CC(=O)C(C)C.COC1=CC2=C(C=C1OC)C(C)(C)C(C)=N2.COC1=CC=C(N)C=C1OC YMCAIWQFMFRKPU-UHFFFAOYSA-N 0.000 description 1
- OKJWRGYZMBBEDP-UHFFFAOYSA-N CC(=O)CCCNC(C)C Chemical compound CC(=O)CCCNC(C)C OKJWRGYZMBBEDP-UHFFFAOYSA-N 0.000 description 1
- UAMQSSQEXOTMBU-UHFFFAOYSA-N CC(=O)CCCNC(C)C.CC(C)CCCN Chemical compound CC(=O)CCCNC(C)C.CC(C)CCCN UAMQSSQEXOTMBU-UHFFFAOYSA-N 0.000 description 1
- NRRPNKQWNUCJSK-UHFFFAOYSA-N CC(=O)OC1=CC=CC=C1C(C)C.CC(C)C1=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C=CC=C1.CC1=CC(C)=[N+]2C1=CC1=CC=C(CCC(C)C)N1[B-]2(F)F.COC1=NC(C)=NC(N(C)C(=O)NS(=O)(=O)C2=CC=CC=C2C(C)C)=N1 Chemical compound CC(=O)OC1=CC=CC=C1C(C)C.CC(C)C1=C(C2=C3C=CC(=O)C=C3OC3=CC(O)=CC=C32)C=CC=C1.CC1=CC(C)=[N+]2C1=CC1=CC=C(CCC(C)C)N1[B-]2(F)F.COC1=NC(C)=NC(N(C)C(=O)NS(=O)(=O)C2=CC=CC=C2C(C)C)=N1 NRRPNKQWNUCJSK-UHFFFAOYSA-N 0.000 description 1
- MBDUYAQZHFDFKX-UHFFFAOYSA-N CC(=O)OC1=CC=CC=C1C(C)C.CC(C)C1=CC=CC=C1/C1=C2\C=CC(=O)C=C2OC2=CC(O)=CC=C21.COC1=NC(C)=NC(N(C)C(=O)NS(=O)(=O)C2=CC=CC=C2C(C)C)=N1 Chemical compound CC(=O)OC1=CC=CC=C1C(C)C.CC(C)C1=CC=CC=C1/C1=C2\C=CC(=O)C=C2OC2=CC(O)=CC=C21.COC1=NC(C)=NC(N(C)C(=O)NS(=O)(=O)C2=CC=CC=C2C(C)C)=N1 MBDUYAQZHFDFKX-UHFFFAOYSA-N 0.000 description 1
- KRABCWHZNBWIKI-UHFFFAOYSA-N CC1=CC(C)=[N+]2C1=CC1=CC=C(CCC(C)C)N1[B-]2(F)F.CCCCC(C)C Chemical compound CC1=CC(C)=[N+]2C1=CC1=CC=C(CCC(C)C)N1[B-]2(F)F.CCCCC(C)C KRABCWHZNBWIKI-UHFFFAOYSA-N 0.000 description 1
- GZCOZFNDDYZCBI-UHFFFAOYSA-O CC1=NC2=C(Br)C=CC(O)=C2C1(C)C.CC1=[N+](C)C2=C(Br)C=CC(O)=C2C1(C)C Chemical compound CC1=NC2=C(Br)C=CC(O)=C2C1(C)C.CC1=[N+](C)C2=C(Br)C=CC(O)=C2C1(C)C GZCOZFNDDYZCBI-UHFFFAOYSA-O 0.000 description 1
- SNLKWIFJUSDJAR-UHFFFAOYSA-N CC1=NC2=C(Br)C=CC(O)=C2C1(C)C.COC1=C2C(=C(Br)C=C1)N=C(C)C2(C)C Chemical compound CC1=NC2=C(Br)C=CC(O)=C2C1(C)C.COC1=C2C(=C(Br)C=C1)N=C(C)C2(C)C SNLKWIFJUSDJAR-UHFFFAOYSA-N 0.000 description 1
- MAFQEUFMYUAROD-UHFFFAOYSA-N CC1=NC2=C(C=C(O)C(O)=C2)C1(C)C.CC1=NC2=C(C=C3OCC(=O)OC3=C2)C1(C)C.O=C(Cl)CCl Chemical compound CC1=NC2=C(C=C(O)C(O)=C2)C1(C)C.CC1=NC2=C(C=C3OCC(=O)OC3=C2)C1(C)C.O=C(Cl)CCl MAFQEUFMYUAROD-UHFFFAOYSA-N 0.000 description 1
- IAFCSXSZYZJWMS-UHFFFAOYSA-N CC1=NC2=C(C=C(O)C(O)=C2)C1(C)C.COC1=CC2=C(C=C1OC)C(C)(C)C(C)=N2 Chemical compound CC1=NC2=C(C=C(O)C(O)=C2)C1(C)C.COC1=CC2=C(C=C1OC)C(C)(C)C(C)=N2 IAFCSXSZYZJWMS-UHFFFAOYSA-N 0.000 description 1
- JTXCUHVGQKKSDE-UHFFFAOYSA-N COC1=C2C=C3/C=C\C4=C5C(=CC=C4)C=CC(=C35)C2=CC=C1C(C)C Chemical compound COC1=C2C=C3/C=C\C4=C5C(=CC=C4)C=CC(=C35)C2=CC=C1C(C)C JTXCUHVGQKKSDE-UHFFFAOYSA-N 0.000 description 1
- XSLPWPCIXKZDKZ-UHFFFAOYSA-N COC1=CC(N)=C(Br)C=C1.COC1=CC([N+](=O)[O-])=C(Br)C=C1 Chemical compound COC1=CC(N)=C(Br)C=C1.COC1=CC([N+](=O)[O-])=C(Br)C=C1 XSLPWPCIXKZDKZ-UHFFFAOYSA-N 0.000 description 1
- IOLQKXSGLQDMCN-UHFFFAOYSA-N COC1=CC([N+](=O)[O-])=C(Br)C=C1.COC1=CC([N+](=O)[O-])=C(N)C=C1 Chemical compound COC1=CC([N+](=O)[O-])=C(Br)C=C1.COC1=CC([N+](=O)[O-])=C(N)C=C1 IOLQKXSGLQDMCN-UHFFFAOYSA-N 0.000 description 1
- WOXNTUCHYKWGTJ-UHFFFAOYSA-N COC1=CC([N+](=O)[O-])=C(N)C=C1.COC1=CC=C(NC(C)=O)C=C1 Chemical compound COC1=CC([N+](=O)[O-])=C(N)C=C1.COC1=CC=C(NC(C)=O)C=C1 WOXNTUCHYKWGTJ-UHFFFAOYSA-N 0.000 description 1
- WXPFZNBKDPNWTN-UHFFFAOYSA-N C[Ni].O=C1C=CC2=CC3=CC=CC=C3C=C2O1.O=C1CCC2=CC3=CC=CC=C3C=C2O1 Chemical compound C[Ni].O=C1C=CC2=CC3=CC=CC=C3C=C2O1.O=C1CCC2=CC3=CC=CC=C3C=C2O1 WXPFZNBKDPNWTN-UHFFFAOYSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Chemical group 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- PQGITROZWNRGCF-UHFFFAOYSA-N NC(CS(=O)(=O)O)C(=O)CC(CS(=O)(=O)O)C(=O)NC(CS(=O)(=O)O)C(=O)O Chemical compound NC(CS(=O)(=O)O)C(=O)CC(CS(=O)(=O)O)C(=O)NC(CS(=O)(=O)O)C(=O)O PQGITROZWNRGCF-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- JKOCGAMDKVAHCI-UHFFFAOYSA-N O=C(C=C1)Oc2c1cc(cccc1)c1c2 Chemical compound O=C(C=C1)Oc2c1cc(cccc1)c1c2 JKOCGAMDKVAHCI-UHFFFAOYSA-N 0.000 description 1
- RTRYXVCRIOKRKZ-UHFFFAOYSA-N O=C(Cl)CCl.O=C1COC2=CC3=CC=CC=C3C=C2O1.OC1=CC2=CC=CC=C2C=C1O Chemical compound O=C(Cl)CCl.O=C1COC2=CC3=CC=CC=C3C=C2O1.OC1=CC2=CC=CC=C2C=C1O RTRYXVCRIOKRKZ-UHFFFAOYSA-N 0.000 description 1
- RIDCJGJGCYLUKU-UHFFFAOYSA-N O=C1Oc(cc(cccc2)c2c2)c2OC1 Chemical compound O=C1Oc(cc(cccc2)c2c2)c2OC1 RIDCJGJGCYLUKU-UHFFFAOYSA-N 0.000 description 1
- KPUFIHPTGQZGSV-UHFFFAOYSA-O O=S(=O)=O.[H]CC(NC(=O)C(CS(=O)(=O)O)NC(=O)C(N)CS(=O)(=O)O)C(=O)NCC1=CC2=C(C=C1)[N+](C)=C(/C=C/C=C/C=C1/N(C)C3=C(C=C(C(C)C)C(OC)=C3)C1(C)C)C2(C)C Chemical compound O=S(=O)=O.[H]CC(NC(=O)C(CS(=O)(=O)O)NC(=O)C(N)CS(=O)(=O)O)C(=O)NCC1=CC2=C(C=C1)[N+](C)=C(/C=C/C=C/C=C1/N(C)C3=C(C=C(C(C)C)C(OC)=C3)C1(C)C)C2(C)C KPUFIHPTGQZGSV-UHFFFAOYSA-O 0.000 description 1
- JRNGUTKWMSBIBF-UHFFFAOYSA-N Oc1cc(cccc2)c2cc1O Chemical compound Oc1cc(cccc2)c2cc1O JRNGUTKWMSBIBF-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000031708 Saprospiraceae Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- APCHGWSMYQKDJW-UHFFFAOYSA-N [H]C(=O)C1=CC2=CC=CC=C2C=C1O.[H]C(=O)C1=CC2=CC=CC=C2C=C1OC Chemical compound [H]C(=O)C1=CC2=CC=CC=C2C=C1O.[H]C(=O)C1=CC2=CC=CC=C2C=C1OC APCHGWSMYQKDJW-UHFFFAOYSA-N 0.000 description 1
- KYMQNNVQEWMPQZ-YQOLPSQSSA-N [H]OC1=CC2=C(C=C1C(C)C)C(C)(C)/C(=C\C=C\C1=N(/C)C3=C(C=CC=C3)C1(C)C)N2C Chemical compound [H]OC1=CC2=C(C=C1C(C)C)C(C)(C)/C(=C\C=C\C1=N(/C)C3=C(C=CC=C3)C1(C)C)N2C KYMQNNVQEWMPQZ-YQOLPSQSSA-N 0.000 description 1
- GGBOADUWFHTSQW-UHFFFAOYSA-O [H]OC1=CC2=C(C=C1C(C)C)C(C)(C)/C(=C\C=C\C1=[N+](C)C3=C(C=CC=C3)C1(C)C)N2C Chemical compound [H]OC1=CC2=C(C=C1C(C)C)C(C)(C)/C(=C\C=C\C1=[N+](C)C3=C(C=CC=C3)C1(C)C)N2C GGBOADUWFHTSQW-UHFFFAOYSA-O 0.000 description 1
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000004171 alkoxy aryl group Chemical group 0.000 description 1
- 125000005248 alkyl aryloxy group Chemical group 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 238000007080 aromatic substitution reaction Methods 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000004467 aryl imino group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000012984 biological imaging Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 125000005621 boronate group Chemical group 0.000 description 1
- 125000001626 borono group Chemical group [H]OB([*])O[H] 0.000 description 1
- 125000000707 boryl group Chemical group B* 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 125000002579 carboxylato group Chemical group [O-]C(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 125000001651 cyanato group Chemical group [*]OC#N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 229910003472 fullerene Inorganic materials 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004997 halocarbonyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- GVLGAFRNYJVHBC-UHFFFAOYSA-N hydrate;hydrobromide Chemical compound O.Br GVLGAFRNYJVHBC-UHFFFAOYSA-N 0.000 description 1
- 125000005027 hydroxyaryl group Chemical group 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000010501 iterative synthesis reaction Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 description 1
- RIFHJAODNHLCBH-UHFFFAOYSA-N methanethione Chemical group S=[CH] RIFHJAODNHLCBH-UHFFFAOYSA-N 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 238000004776 molecular orbital Methods 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000005648 named reaction Methods 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000012014 optical coherence tomography Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- 125000000394 phosphonato group Chemical group [O-]P([O-])(*)=O 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000006552 photochemical reaction Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000858 thiocyanato group Chemical group *SC#N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/08—Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor
- B01J19/12—Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing electromagnetic waves
- B01J19/122—Incoherent waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
Definitions
- the present disclosure relates to compounds capable to deliver a payload in a controlled fashion.
- the present disclosure relates to photoacid compounds and related compositions methods and systems.
- Targets to specific environments e.g. delivery of pesticides, delivery of chemicals such as a fluorescent dye on a biological or non-biological system, such as specific cell types and/or tissues of individuals in vitro and/or in vivo is currently still challenging, especially when directed at providing controlled release of the target in a controllable conformation, typically associated to a biological or chemical activity.
- chemicals such as a fluorescent dye on a biological or non-biological system, such as specific cell types and/or tissues of individuals in vitro and/or in vivo is currently still challenging, especially when directed at providing controlled release of the target in a controllable conformation, typically associated to a biological or chemical activity.
- photoacid compounds and related compositions, methods, and systems that in some embodiments permit the uncaging and release of a payload molecule upon irradiation with a suitable wavelength light.
- a photoacid compound comprises a light absorbing moiety attaching a payload moiety through a linker moiety.
- the linker moiety comprises a geminal dialkyl moiety linked to an ester group having a carbonyl oxygen, the carbonyl group of the ester attaching the payload moiety.
- the light absorbing moiety attaches the linker moiety in ortho position to a hydroxyl group and the linker is configured to present the carbonyl oxygen for reaction with the hydroxyl group.
- a photoacid compound having the general structure according to formula (I):
- a method to deliver a compound comprises providing a caged compound, the caged compound being caged as a payload moiety within the photoacid compound herein described and in particular with a photoacid compound of Formula (I), the photoacid compound being in a ground state in which the hydrogen substituted heteroatom presented on the light absorbing moiety of the photoacid compound has a ground state pK a .
- the method for uncaging the caged compound by irradiating the photoacid compound with light at a wavelength suitable to promote the photoacid compound to an excited state wherein the hydrogen substituted heteroatom presented on the light absorbing moiety of the photoacid compound has an excited state pK a lower than the ground state pK a .
- a system to deliver a compound comprising at least two of: one or more photoacids compounds, and in particular one or more photoacid compounds of Formula (I) and a light source suitable to irradiate light at a suitable wavelength, for simultaneous, combined or sequential use in methods herein described.
- Photoacid compounds herein described and related compositions, methods and systems allow in several embodiments controlled release of a payload moiety in various chemical and biological environments.
- photoacid compounds herein described and related compositions methods and systems allow controlled release of a payload moiety upon irradiation at a wavelength of at least about 750 nm or higher.
- Photoacid compounds herein described and related compositions, methods and systems can be used in connection with applications wherein controlled delivery of a compound is desired.
- Exemplary applications comprise applications in medical field, biological and chemical research, such as drug development, molecule studies, light-activated therapies and strategies for imaging biological systems.
- FIG. 1 shows a schematic illustration of photoacid compounds herein described and of related methods and systems.
- FIG. 1A shows a schematic representation of a method to uncage a drug comprised as a payload in photoacid compound wherein the light absorbing moiety is formed by a NIR absorber.
- FIG. 1B shows a known reaction scheme of uncaging of a water molecule in a photoacid after protonation of a hydroxyl group wherein the protonation is induced by the increase in acidity of the photoacidic hydrogen.
- FIG. 1 shows a schematic illustration of photoacid compounds herein described and of related methods and systems.
- FIG. 1A shows a schematic representation of a method to uncage a drug comprised as a payload in photoacid compound wherein the light absorbing moiety is formed by a NIR absorber.
- FIG. 1B shows a known reaction scheme of uncaging of a water molecule in a photoacid after protonation of a hydroxyl group wherein
- FIG. 1C shows a schematic of the novel protonation of a carbonyl group in a linking moiety and subsequent uncaging of a payload moiety of a generic photoacid compound after irradiation of the light absorbing moiety with light resulting in an increase in the acidity of the photoacidic proton.
- FIG. 1D shows the uncaging of a particular photoacid compound by irradiation of the photoacid compound with light resulting in the release of hydrocinnamic acid.
- FIG. 1E shows a schematic structure of an exemplary generic photoacid compound with an acene light absorbing moiety in which expansion of the acene chromophores allows absorption of a longer wavelength light.
- FIG. 1F shows an exemplary photoacid compound as herein described with a retinal/carotene-type light absorbing moiety.
- FIG. 1G shows an exemplary photoacid compound as herein described with a cyanine-type light absorbing moiety.
- FIG. 1 H shows the uncaging of a particular photoacid compound by irradiation of the photoacid compound with light resulting in the release of ⁇ -aminobutyric acid with concomitant decarboxylation to release CO 2 .
- FIG. 2 shows a schematic of a ring opening reaction of a fluorescein molecule that results in fluorescence.
- FIG. 3 shows a schematic of a synthetic scheme for the synthesis of photoacid compounds with a naphthol-based light absorbing moiety.
- FIG. 4 shows a schematic of a synthetic scheme for the synthesis of photoacid compounds with a cyanine-based light absorbing moiety.
- FIG. 5 shows a schematic of a synthetic scheme for the synthesis of photoacids with a cyanine-based light absorbing moiety.
- FIG. 6 shows LC-MS traces for an exemplary photoacid compound as herein described before and after irradiation with light to uncage the payload moiety.
- FIG. 7 shows a schematic of a synthetic scheme for the synthesis of a photoacid compound with X 1 is C.
- FIG. 8 shows a schematic of general synthetic schemes for the synthesis of cyanine-based photoacid compounds as herein described.
- FIG. 8A shows a general synthetic strategy to synthesize photoacid compounds of Formula (I) using a common precursor (ortho dihydroxyarene; 32).
- FIG. 8B shows a general synthetic scheme for the synthesis of closed chain cyanines with a variable-length polyene and variable heteroaryl groups.
- FIG. 8C shows an exemplary application of the synthesis shown in FIG. 8B to the general synthesis of photoacid compounds with cyanine light absorbing moieties.
- FIG. 8A shows a general synthetic strategy to synthesize photoacid compounds of Formula (I) using a common precursor (ortho dihydroxyarene; 32).
- FIG. 8B shows a general synthetic scheme for the synthesis of closed chain cyanines with a variable-length polyene and variable heteroaryl groups.
- FIG. 8C shows an exemplary application of the synthesis shown in FIG. 8B to
- FIG. 8D shows a photoactive molecule with a particular desired absorbance wavelength (compound 40) and an analogous photoactive compound as herein described (compound 41) incorporating compound 40 as the light absorbing moiety.
- FIG. 8E shows the synthesis of a quinolinium compound that can be used in the synthesis of cyanines.
- FIG. 8D shows a photoactive molecule with a particular desired absorbance wavelength (compound 40) and an analogous photoactive compound as herein described (compound 41) incorporating compound 40 as the light absorbing moiety.
- photoacid compounds and related compositions, methods, and systems that in some embodiments permit the uncaging and release of caged payload molecules upon irradiation with long wavelength light.
- photoacid refers to a compound that can be switched from a ground state to an excited state upon absorption of light, and that has an excited state acidity associated to the excited states higher than a ground state acidity associated to the ground state.
- excited state refers to an electronic state of a moiety in which the molecule has absorbed light energy and been promoted to a higher energy state. This process is referred to as “excitation.”
- ground state refers to the electronic state of a moiety in which the electrons are in their lowest energy molecular orbitals.
- the excitation can be accomplished, for example, by irradiating a photoacid molecule with light of energy equal to the difference in energy between the ground state and the excited state.
- the light used to effect the excitation is infrared or near infrared light.
- molecules that can undergo excitation to an excited state are typically molecules comprising systems of conjugated ⁇ bonds such as those present in polyaromatic (e.g. polycyclic aromatic hydrocarbons) and polyene (e.g. cyanine and carotene molecules) molecules.
- polyaromatic e.g. polycyclic aromatic hydrocarbons
- polyene e.g. cyanine and carotene molecules
- the energy required to excite a molecule such as a photoacid can be decreased, which results in light of longer wavelengths being able to excite the molecule, by increasing the size of the system of conjugated ⁇ bonds (see, e.g., [Ref 1]).
- Determination of the excited states for a certain compound and the related level of energy can be performed by a skilled person using methods and techniques identifiable by a skilled person.
- the excited states can be determined by measuring the absorption spectrum of a compound and thus the wavelengths of light absorbed by the compound via spectrophotometry.
- a “photoacid” in the sense of the present disclosure typically comprises a light absorbing moiety presenting an hydrogen substituted heteroatom.
- a shift in acidity following light absorbance by the light absorbing moiety can be detected by detecting the pK a of a hydrogen substituted heteroatom which is presented on the light absorbing moiety of the photoacid.
- Detection of the pK a of the hydrogen substituted heteroatom can be performed according to techniques and methods identifiable by a skilled person (see e.g. [Ref 2] and [Ref 3]).
- Exemplary photoacids include hydroxyaryls such as 2-naphthol which displays a ground state pK a of 9.5 and an excited state pK a (pK a *) of 2.8 (see, e.g., [Ref 4]).
- the pK a * of a photoacid can be determined, for example, by combining the Förster cycle with the pK a of the photo acid in its ground state to perform calculations known to those in the art, as well as by fluorescence titrations (see, e.g., [Ref 2] and [Ref 3]).
- the photoacid compound of the disclosure comprise a light absorbing moiety which is attached to a payload moiety through a linker comprising a geminal dialkyl moiety which presents a carbonyl group attaching the payload moiety.
- the linker is configured to present the carbonyl oxygen in proximity to the hydroxyl of the light absorbing moiety and is further configured such that the hydroxy is ortho to the linker.
- attach refers to connecting or uniting by a covalent bond in order to keep two or more components together, which encompasses either direct or indirect attachment where, for example, a first moiety is directly bound to a second moiety, or one or more intermediate moieties are disposed between the first moiety and the second moiety.
- present indicates attachment performed to maintain the chemical reactivity of the compound or functional group as attached. Accordingly, for example a carbonyl group presented on a linker, is able to perform under the appropriate conditions the one or more chemical reactions that chemically characterize the carbonyl group.
- the wording “present for reaction”, with reference to a compound or a functional group indicates attachment performed to maintain the chemical reactivity of the compound or functional group as attached, such that the attachment is performed in a configuration that allow the specific reaction mentioned. Accordingly, a carbonyl group presented for reaction with an hydroxyl group indicates a configuration in which the carbonyl group is in a position allowing a chemical reaction with the hydroxyl group.
- light absorbing moiety indicates moiety that is converted to an excited states upon absorption of light at a predetermined wavelength.
- Exemplary light absorbing moieties comprise long wavelength absorbing moieties (LWAP) able to absorb light at a wavelength greater than or equal to 750 nm, and more particularly a wavelength in a range from about 900 to about 1100 nm.
- Additional exemplary light absorbing moieties comprise short wavelength light absorbing moieties (SWAP) able to absorb light at a wavelength less than 750 nm and in particular at a wavelength from about 500 nm to about 750 nm and a wavelength from about 600 nm to about 750 nm.
- the light absorbing moiety comprises a substituted or unsubstituted polycyclic aromatic hydrocarbon or substituted or unsubstituted closed chain cyanine or hemicyanine dye presenting a hydroxyl group in which the hydroxyl group is covalently bound to the substituted or unsubstituted polycyclic aromatic hydrocarbon or substituted or unsubstituted closed chain cyanine or hemicyanine dye.
- the hydroxyl group can be covalently bound to a carbon of the substituted or unsubstituted polycyclic aromatic hydrocarbon or substituted or unsubstituted closed chain cyanine or hemicyanine dye such that the hydroxyl is ortho to the linker herein described.
- linker indicates to an organic structure configured to connect two moieties to form a stable chemical structure.
- linker in the sense of the present disclosure can be formed by a mono or dialkoxy moiety comprising the dialkyl germinal group and presenting the carbonyl group for reaction.
- payload refers to a moiety carried by a compound in a configuration that allows the relevant delivery under controllable parameters.
- a payload is a moiety is connected to the linker and forms part of the photoacidic compounds herein described.
- a payload indicates an organic moiety configured to attach the carbonyl group of the linker of a photoacid compound herein described.
- a photoacid compound herein described has of the general structure according to Formula (I):
- R 4 can be a moiety of Formula (III):
- n is between 0 and 5.
- R 4 can be a moiety of Formula (IV):
- n is between 0 and 5
- m is between 1 and 3.
- R 4 can be a moiety of Formula (V):
- R a and R b are independently H, alkyl, or O-alkyl; Y is N, O, or S; and p is between 1 and 4.
- R 4 can be a moiety of Formula (VI):
- R c and R d are independently alkyl and q is between 1 and 4.
- R 4 can be a moiety of Formula (VII):
- r is between 1 and 4.
- R 4 can be a moiety of Formula (VIII):
- the light absorbing moiety and herein described can be substituted or unsubstituted and in particular have additional substituents which can be added to impart additional functionalities such as, for example, hydrophilic substituents (e.g. sulfonate, and in particular polysulfonates such as polysulfonate peptides or oligopeptides, as well as polyethylene glycol groups), and functional groups and/or moieties to connect the photoacid compounds herein described to other molecules and/or substances (e.g. for connection to carbon nanotubes, fullerenes, antibodies, polymers, proteins, lipids, carbohydrates, and others identifiable to a skilled person).
- hydrophilic substituents e.g. sulfonate, and in particular polysulfonates such as polysulfonate peptides or oligopeptides, as well as polyethylene glycol groups
- functional groups and/or moieties to connect the photoacid compounds herein described to other molecules and/or substances (e.
- the photoacid attaches a payload and in particular a payload R 3 in a photoacid of Formula (I).
- R 3 can be an organic moiety such as, for example a substituted or unsubstituted alkyl, aryl, heteroaryl, alkoxy, alkylamino, or dialkylamino moiety.
- R 3 is adapted to exist in a carboxylic acid form wherein the carboxylic acid form can be used to provide the carbonyl group of the linker of Formula (II) (see Example 1 and Example 3).
- R 3 can be a moiety of Formula (IX):
- R ⁇ is H, or substituted or unsubstituted alkyl, alkylamino, alkoxy, aryl, arylamino, aryloxy, heteroaryl, hetroarylamino, and heteroaryloxy;
- X is C or N; and wherein when q is greater than 1, each R′ is independent of the other R ⁇ substituents.
- R 3 is according to Formula (IX)
- R 3 can be selected from the group consisting of Formulas (X)-(XII):
- R 3 can be a moiety of Formula (XIII):
- R ⁇ , R ⁇ , and R ⁇ are independently H, or substituted or unsubstituted alkyl, alkylamino, alkoxy, aryl, arylamino, aryloxy, heteroaryl, hetroarylamino, and heteroaryloxy; and wherein when n is greater than 1, the R ⁇ and R ⁇ of each C(R ⁇ )(R ⁇ ) unit are independent of the R ⁇ and R ⁇ of the other units.
- R 3 is according to Formula (XIII)
- R 3 can be selected from the group consisting of Formulas (XIV) and (XV):
- R 3 can be a moiety of Formula (XVI):
- R ⁇ , R ⁇ , and R ⁇ are independently H, or substituted or unsubstituted alkyl, alkylamino, alkoxy, aryl, arylamino, aryloxy, heteroaryl, hetroarylamino, and heteroaryloxy; wherein R ⁇ is H, substituted or unsubstituted alkyl, acyl, aryl; and wherein when p is greater than 1, the R ⁇ and R ⁇ of each C(R ⁇ )(R ⁇ ) unit are independent of the R ⁇ and R ⁇ of the other units.
- R 3 is according to Formula (XVI):
- R 3 can be a peptide or oligopeptide such that the peptide or oligopeptide is attached to the linker via the N-terminus of the peptide or oligopeptide.
- R 3 can be a moiety of Formula (XVIII):
- R ⁇ , R ⁇ , and R ⁇ are independently H, or substituted or unsubstituted alkyl, alkylamino, alkoxy, aryl, arylamino, aryloxy, heteroaryl, hetroarylamino, and heteroaryloxy; and wherein when m is greater than 1, the R ⁇ and R ⁇ of each C(R ⁇ )(R ⁇ ) unit are independent of the R ⁇ and R ⁇ of the other units.
- R 3 can be a moiety of Formula (XIX):
- R ⁇ is H, or substituted or unsubstituted alkyl, alkylamino, alkoxy, aryl, arylamino, aryloxy, heteroaryl, hetroarylamino, and heteroaryloxy; c is a substituted or unsubstituted hydrocarbylene, X is C or N; and wherein when q is greater than 1, each R ⁇ is independent of the other R ⁇ substituents.
- the payload moiety and in particular the payload molecule R 3 is a molecule for which controlled disconnection and release from the photoacid compound is desired.
- exemplary payload molecules include imaging agents, drug molecules, fluorescent dyes, pesticides, pigments, neurotransmitter; anti-cancer agents; sedatives; antibodies; protein therapeutics and others identifiable to a skilled person upon a reading of the present disclosure.
- the payload R 3 can be attached to R 4 through the linker of formula (II).
- X 1 can be independently O or C.
- R 1 and R 2 are methyl groups or other C 1 -C 6 alkyl groups or cycloalkyl. In other embodiments, R 1 and R 2 are linked to form a cyclic moiety such as a cyclopentyl or cyclohexyl moiety.
- the light absorbing moiety R 4 is a moiety according to Formula (III); and the linker is a linker of Formula (II) wherein X 1 is O and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the linker is a linker of Formula (II) wherein X 1 is C and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the light absorbing moiety R 4 is a moiety according to Formula (III) wherein n is 0; and the linker is a linker of Formula (II) wherein X 1 is O and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the light absorbing moiety R 4 is a moiety according to Formula (III) wherein n is 0, the linker is a linker of Formula (II) wherein X 1 is C and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the light absorbing moiety R 4 is a moiety according to Formula (IV); and the linker is a linker of Formula (II) wherein X 1 is O and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the light absorbing moiety R 4 is a moiety according to Formula (IV); and the linker is a linker of Formula (II) wherein X 1 is C and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety
- the light absorbing moiety R 4 is a moiety according to Formula (IV) wherein m is 2 and n is 0; and the linker is a linker of Formula (II) wherein X 1 is O and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the light absorbing moiety R 4 is a moiety according to Formula (IV) wherein m is 2 and n is 0; and the linker is a linker of Formula (II) wherein X 1 is C and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the light absorbing moiety R 4 is a moiety according to Formula (V); and the linker is a linker of Formula (II) wherein X 1 is 0 and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the light absorbing moiety R 4 is a moiety according to Formula (V); and the linker is a linker of Formula (II) wherein X 1 is C and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the light absorbing moiety R 4 is a moiety according to Formula (VI), and the linker is a linker of Formula (II) wherein X 1 is O and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the light absorbing moiety R 4 is a moiety according to Formula (VI); and the linker is a linker of Formula (II) wherein X 1 is C and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the light absorbing moiety R 4 is a moiety according to Formula (VI) wherein q is 2, and the linker is a linker of Formula (II) wherein X 1 is O and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the light absorbing moiety R 4 is a moiety according to Formula (VI) wherein q is 2; and the linker is a linker of Formula (II) wherein X 1 is C and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the light absorbing moiety R 4 is a moiety according to Formula (VII), and the linker is a linker of Formula (II) wherein X 1 is O and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the light absorbing moiety R 4 is a moiety according to Formula (VII); and the linker is a linker of Formula (II) wherein X 1 is C and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the light absorbing moiety R 4 is a moiety according to Formula (VII) wherein r is 2, and the linker is a linker of Formula (II) wherein X 1 is O and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the light absorbing moiety R 4 is a moiety according to Formula (VII) wherein r is 2; and the linker is a linker of Formula (II) wherein X 1 is C and R 1 and R 2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- the photoacid compounds of the disclosure can be used in methods and systems to deliver the payload R 3 in a controlled fashion.
- a payload R 3 can be released or decaged by providing the light absorbing moiety of the photoacid with a wavelength suitable to switch the state of the light absorbing moiety R 4 from a ground state to an excited state.
- the term “cage” as used herein relates to the interaction between a first chemical moiety and a second chemical moiety that minimizes the participation in physical chemical or biological reactions of the second chemical moiety.
- the payload is caged by the linker moiety through covalent bond of the carbonyl group of the linker with a suitable functional group in the linker.
- the terms “decage” or “uncage” herein are defined as a modification of a caging interaction between a first and second chemical moiety to the chemical moiety, forming liberating the second molecule to participate in chemical or biological reactions.
- decaging is performed through cleavage of the covalent bond between carbonyl group and the payload. Decaging of a compound can be detected by identifying the decaged activity of the uncaged compound or by LC-MS spectroscopy to identify either the caged compound, the first moiety, or the second moiety.
- a suitable wavelength can be selected based on known photoactive molecules (e.g. polycyclic aromatic hydrocarbons and/or cyanine; see, e.g., [Ref 1]) which can then be subjected to the appropriate preparation methods exemplified in Examples 1-4 and Examples 7-8.
- photoactive molecules e.g. polycyclic aromatic hydrocarbons and/or cyanine; see, e.g., [Ref 1]
- the wavelength is selected so that the promotion of the light absorbing moiety R 4 from a ground state to an excited state results in a decrease of the pK a of the photoacidic R 4 OH group relative to the pK a of the same OH group in the ground state.
- the consequent shifting of the acid base equilibrium of the photoacid results in the release of payload R 3 .
- detection of the successful switching to an excited state by the light absorbing moiety R 4 following irradiation of the photoacids with a suitable wavelength can be performed by detecting a switching in acidity in the reaction solution performed by measuring pK a of the photoacidic R 4 hydroxyl group.
- providing a caged compound can be performed by synthesizing a photoacid of Formula (I) including the compound caged as a payload moiety.
- the photoacid compound is selected to have a light absorbing moiety with a OH group such that upon irradiation with light at a wavelength exciting the light absorbing moiety the pK a of the OH group is lowered.
- the light absorbing moiety can be formed by a LWAP which is promoted to an excited state upon irradiation with an infrared light or a near infrared light (or NIR).
- infrared light refers to light in the infrared region of the electromagnetic spectrum from approximately 0.75 ⁇ m to 1000 ⁇ m.
- near infrared refers to a region of the infrared spectrum from approximately 0.75 ⁇ m (750 nm) to 1.4 ⁇ m (1400 nm).
- FIG. 1A presents a schematic illustration of a light activated photoacid releasing according to the present disclosure, where a long-wavelength absorber is linked to the exemplary payload moiety formed by a drug, the drug being replaceable by an imaging agent or other payload molecule as will be understood by a skilled person.
- FIG. 1B shows a UV-activated photoacid releasing water, through photoactive protonation of an hydroxyl alcohol presented by a naphthyl moiety resulting in the release of water to be considered in comparison with FIG. 1C showing an exemplary light activated photoacid releasing according to the present disclosure in which the light absorbing moiety is a napthol.
- FIG. 1A presents a schematic illustration of a light activated photoacid releasing according to the present disclosure, where a long-wavelength absorber is linked to the exemplary payload moiety formed by a drug, the drug being replaceable by an imaging agent or other payload molecule as will be understood by a skilled person.
- FIG. 1B shows
- the system is designed to have a photoacidic group (the OH), and an ester that can intramolecularly hydrogen bond to the OH.
- the ester is a derivative of a t-butyl ester, a class that is especially sensitive to acid-catalyzed ester cleavage.
- t-Butyl esters suitable for inclusion in a linker herein described comprise t-butyl esters commonly used in commercial solid phase peptide synthesizers and t-butyl esters that are part of the common Boc protecting group.
- the standard t-butyl cleavage mechanism can produce a generic carboxylate.
- cleavage in this system releases the generic entity RCO 2 H, a carboxylic acid, which, under physiological conditions will be in its deprotonated, carboxylate form (structure in box).
- RCO 2 H a carboxylic acid
- the photochemical excited state can increase the acidity of appropriate groups by as many as 10 orders of magnitude ([Ref 5] and [Ref 6]). Such an increase in acidity is intramolecular and hence usually does not alter the pH of the surrounding environment.
- the shift in acidity (pK a ) of about 10 orders of magnitude is corresponds to only an energy change of ⁇ 14 kcal/mol, which supports the conclusion that suitable light absorbing moiety for the photoacid compounds herein described can absorb a very long wavelength light (e.g. from about 900 to about 1100 nm) and that various moiety that can be excited at long wavelength are expected to be able to initiate photoacid chemistry. For example, light at 1010 nm has an energy of 28 kcal/mol, twice what is needed to produce the desired pK a shift.
- FIG. 1D shows a proof of concept establishing viability of the essential photochemical reaction proposed (see also Example 5 showing that irradiation produces the carboxylic acid shown).
- FIG. 1E shows how the light-absorbing feature of the molecule—the chromophore—can be varied while leaving the essential chemistry intact. As the chromophore gets larger, it can absorb longer wavelength light such as, for example, long wavelength visible light and/or NIR light. Even at wavelengths far out into the NIR, enough energy can be present to enhance the pK a of the OH. For example, light at 1010 nm (commonly used in optical coherence tomography) has an energy of 28 kcal/mol, twice what is needed or a factor of 10 orders of magnitude.
- the light absorbing moieties described herein can be selected to absorb longer wavelengths of light.
- known dyes and NIR absorbers can permit empirical determination which systems are most effective (see, for example, [Ref 1]).
- FIG. 1F shows a retinal/carotene-type compound that can be continuously tuned by just increasing the number of double bonds. In this approach, the molecule left after uncaging resembles carotene or vitamin E, and can exert non-toxic activity.
- FIG. 1G shows a merocyanine dye strategy. These are very common, highly tunable structures that have seen extensive biological use in the form of the common Cy and Alexa dyes ([Ref 7]) and possess arene and heteroarene moieties suitable to the preparation reactions of Examples 1-4 and Examples 7-8.
- FIG. 1H shows uncaging of an amine, in this particular case producing the inhibitory neurotransmitter ⁇ -aminobutyric acid (GABA).
- GABA inhibitory neurotransmitter ⁇ -aminobutyric acid
- This strategy can be used to uncage many compounds including, for example, neurotransmitters, anti-cancer agents, sedatives, antibodies, protein therapeutics, imaging markers, and others.
- a compound such as etomidate can be caged in several ways.
- the unfunctionalized N of the imidazole ring of etomidate can be acylated to produce a structure that can be acid cleaved.
- carboxyl derivatives at C2 of etomidate (between the two nitrogens) decarboxylate when hydrolyzed, feeding naturally into the t-butyl ester strategy herein described. From the structure shown above, the unfunctionalized N of the imidazole ring of etomidate provides a handle for attaching a photocage.
- fluorescein is a common dye that is often used in biological imaging. It exists in two forms that can interconvert ( FIG. 2 ). Either the carboxylic acid or the OH of the fluorescein could be caged within the photoacid compounds described herein. The caged compound would not be fluorescent. Photonic uncaging would liberate fluorescein, allowing an array of imaging strategies to evaluate the efficiency and localization of the photonic uncaging. Of course, many other dyes and imaging agents could be manipulated in the same way.
- the photochemical excited state can increase the acidity of appropriate groups by as many as 10 orders of magnitude ([Ref 5] and [Ref 6]). In those embodiments, such an increase in acidity is intramolecular and hence does not alter the pH of the surrounding environment.
- a suitable wavelength provides an energy change of ⁇ 14 kcal/mol and results in shifting an acid-base equilibrium (pK a ) by 10 orders of magnitude.
- pK a acid-base equilibrium
- such a shift is associated to a wavelength of from about 900 to about 1100 nm).
- light at 1010 nm has an energy of 28 kcal/mol, twice what is needed to produce the desired pK a shift. Additional embodiments will be identifiable to a skilled person upon reading of the present disclosure.
- the photoacids are expected to be tunable with regard to lifetime and absorption spectrum.
- the excited-state lifetimes of these molecules are short, which could limit the efficiency of the proton-transfer reaction.
- several strategies for enhancing excited state lifetimes are known, including adding heavy atoms to facilitate conversion to the longer-lived triplet excited state.
- the addition of electron-withdrawing substituents at key points in the extended ⁇ system can create “super photoacids” which deprotonate very efficiently in aqueous solutions upon excitation.
- photoacidic molecules can be based on 2-naphthols, which display the desired photoacid effect, have a good safety profile, and can be easily modified to control water-solubility and to the tune the optical properties (see e.g. schematized in FIG. 1C and FIG. 1D ).
- the long wavelength light used to uncage the payload is infrared light.
- the infrared light is of a wavelength between 750 nm and 1400 nm corresponding to near infrared light.
- the near infrared light used to uncage the payload compounds can be between 900 and 1100 nm.
- the method for and uncaging the caged compound by irradiating the photoacid compound of Formula (I) with light at a wavelength suitable to promote the photoacid compound of Formula (I) to an excited state wherein the hydrogen substituted heteroatom presented on the light absorbing moiety of the photoacid compound has an excited state pK a lower than the ground state pK a .
- Irradiating can be performed through various procedures and techniques identifiable by a skilled person.
- a long wavelength light can be delivered by any of a number of means such as via microscope, endoscope, LCD panel or LED display as handheld or non-portable devices or worn as glasses or other such attachment to the body.
- Image intensifiers can be used to further increase the emitted power from such devices in order to activate the preparation of molecules.
- high intensity short wavelength light can be used and are suitable for applications in which use of the short length is desired.
- use of a high intensity short wavelength can be used in application wherein production of reactive oxygen species or genetic manipulation of host cells is desired.
- Photoacid compounds described herein can be provided as a part of systems to deliver compounds, identifiable by a skilled person upon reading of the present disclosure.
- the systems for delivery of the caged compounds herein described can be provided in the form of combinations of photoacid compounds and/or related compositions, in which the system can comprise one or more photoacid compounds, and a suitable vehicle identifiable by a skilled person.
- kits of parts can be provided in the form of kits of parts.
- one or more photoacid compounds herein described, and suitable light source and other reagents to perform the reactions can be comprised in the kit independently.
- the photoacid compounds can be included in one or more compositions, and each photoacid compounds can be in a composition together with a suitable vehicle.
- vehicle indicates any of various media acting usually as solvents, carriers, binders or diluents for the caged compounds that are comprised in the composition as an active ingredient.
- the following examples illustrate exemplary photoacid in which the light absorbing moiety is formed by naphthol, and cyanine, X 1 is an 0 or a C, R 1 and R 2 are either methyl or are linked to form a cycloalkyl moiety and the payload hydrocinnamic acid and related methods and systems.
- X 1 is an 0 or a C
- R 1 and R 2 are either methyl or are linked to form a cycloalkyl moiety
- the payload hydrocinnamic acid and related methods and systems
- chloroacyl chlorides can be selected to increase the ring size of the lactone thereby being able to produce different values of n in the photoacid compounds of Formula (I).
- 3-chloropropionyl chloride and 4-chlorobutyryl chloride can be used in place of chloroacetyl chloride to provide photoacid compounds of Formula (I) with values of n of 2 and 3, respectively.
- reaction is not limited to 3,4-dihydroxynaphthalene and that the above strategy can be applied to other ortho dihydroxyaryl and heteroaryl molecules to provide light absorbing moieties with different functional groups on the light absorbing moiety.
- hydroxyl groups can be placed on an arene or heteroarene using methods known to a skilled person (e.g. aromatic substitution reactions).
- an aryl or heteroaryl ring can be subjected to nitration/reduction reactions to afford ortho diamino aryl or heteroaryl rings which can then be subjected to the Sandmeyer reaction (see, e.g. [Ref 10]) using water to convert the amino groups into hydroxyl groups to afford ortho dihydroxy aryl and heteroaryl molecules.
- Lactone 3 is dissolved in dry tetrahydrofuran (THF; 0.2 M) under argon and cooled to 0° C.
- Methylmagnesium bromide (MeMgBr; 2.2 eq, 3.0 M in diethyl ether) is added dropwise and the reaction is allowed to warm to room temperature. After one hour, a solution of hydrocinnamoyl chloride (2.2 eq) in dichloromethane is added dropwise, and the mixture is stirred overnight. Upon completion, the reaction is quenched with saturated aqueous sodium bicarbonate, and extracted with dichloromethane. The combined organics are dried over MgSO 4 , filtered and concentrated in-vacuo. The crude is flashed on silica-gel eluting with 10% ethyl acetate (EtOAc) in hexane to yield the product (4) as a crude oil.
- Methylmagnesium bromide (MeMgBr;
- Grignard reagents can be chosen such that groups other than methyl can be substituted in the positions corresponding to R 1 and R 2 in Formulas (I)-(II) described herein.
- a bis-Grignard reagent could be used to synthesize a compound in which R 1 and R 2 are they are linked together to form a cyclic moiety. Such an exemplary reaction is:
- the acid chloride used in the reaction can comprise the payload compound (R 3 ) and that payload compounds other than the phenylethyl payload of compound 4a can be incorporated by choice of the appropriate acid chloride.
- payload compounds other than the phenylethyl payload of compound 4a can be incorporated by choice of the appropriate acid chloride.
- acid anhydrides, activated esters, and other activated carboxylic acid derivatives can be used instead of an acid chloride.
- Diester 4 (0.1 M) is dissolved in 1:1 THF-methanol (MeOH) and cooled to 0° C. An aqueous solution of LiOH (3.0 eq, 1.0 M) is added dropwise and the reaction is warmed to room temperature. After 2.5 hours, the reaction is quenched with aqueous citric acid, and extracted with dichloromethane. The combined organics are dried over MgSO 4 , filtered and concentrated in-vacuo. The crude is flashed on silica-gel eluting with 20% EtOAc in hexane to yield the product (1) as a clear oil.
- Example 1 A skilled person would recognize that the synthesis of the naphthalene-based photoacid compound 1 in Example 1 can be modified to synthesize acene-based photoacid compounds with more than two fused aryl rings. For example, a skilled person could apply the methods of Lin et al. (“Iterative synthesis of acenes via homo-elongation” Chem. Commun. 2009(7): 803-805) to perform the reaction:
- aldehyde groups (R) can be further converted into amines (e.g., by reductive amination; see, e.g., [Ref 12]).
- the amines can further be functionalized by standard peptide coupling techniques (see e.g. [Ref 13]) with sulfonate peptides such as, for example:
- the substituent of compound 49 can be added to a pendent functional group (e.g. an amine) on the light absorbing moiety (see Examples 1-4).
- a substituent can provide, for example, a compound according to Formula (XX):
- R is CH 2 NH 2 or another moiety according such as 49, and n is between 0 and 5; or a compound according to Formula (XXI):
- 3,4-dimethoxyaniline (6; 0.1 M) is dissolved in 1:1 HCl—H 2 O and cooled to ⁇ 10° C. under argon.
- a chilled aqueous solution of NaNO 2 (1.1 eq) is added slowly via syringe, ensuring that the reaction maintains a temperature below 0° C.
- a chilled solution of 5 nCl 2 (3 eq, 2.0 M) in concentrated HCl followed by 3-methyl-2-butanone (3 eq) is added.
- the mixture is stirred 30 minutes, then quenched into a vigorously stirred solution of aqueous sodium bicarbonate and EtOAc.
- Dimethoxyindolenine 7 (0.1 M) is dissolved in dry DCM under argon, and cooled to 0° C. BBr 3 (2.2 eq) is added dropwise, and the mixture is allowed to warm to r.t. After stirring 3 hours, the reaction is diluted in water, and adjusted to pH 5 using solid sodium acetate. The mixture is extracted with DCM, and the combined organics are dried over Na 2 SO 4 , filtered, and concentrated in-vacuo. The residue is flashed on 5% MeOH in DCM with 1% acetic acid to obtain the desired product (8) as a brown solid.
- additional functional groups can be placed on the indole rings of the cyanine by choosing the appropriate aniline derivative similar to compound 6 above.
- Such different functional groups can be selected, for example, to modulate the wavelength of light absorbed by the light absorbing molecule (see e.g. [Ref 1] and [Ref 19]), to attach groups for increasing water solubility (see e.g., Example 2), or to attach heavy atoms for increasing excited state lifetimes (see e.g., Example 4).
- alkyl iodides can be selected as in the synthesis of compound 11 above to place different alkyl substituents on the indole nitrogens in the final cyanine, for example, to modulate the wavelength of light absorbed by the light absorbing molecule (see e.g. [Ref 1] and [Ref 19]).
- Compound 20 is dissolved in iodomethane and refluxed overnight. After cooling to room temperature, the excess iodomethane is removed in-vacuo. The resulting residue is used without further purification.
- linker with X 1 in Formulas (I) and (II) being C can be synthesized according to the synthesis scheme of FIG. 7 (see, e.g., [Ref 20]).
- FIG. 7 see, e.g., [Ref 20].
- 3-hydroxy-2-naphthaldehyde (27; 1 eq, 0.1 M) is dissolved in dry DCM under Ar and cooled to 0° C. A solution of AlCl 3 (1 eq, 1.0 M) in dry DCM is added, and the mixture is warmed to room temperature. Upon completion, the reaction is quenched with water, extracted with DCM, dried MgSO 4 , filtered and concentrated.
- the aldehyde may be a precursor such as an alcohol or ester which may be oxidized or reduced, respectively, to afford an aldehyde.
- the aldehyde (1 eq, 0.1 M) and (carbethoxymethylene)triphenylphosphorane (1.1 eq) are dissolved in dry xylene under Ar and refluxed 13 hours.
- the solution is diluted in water, and extracted EtOAc, dried MgSO 4 , filtered and concentrated in-vacuo.
- Aqueous LiOH (3 eq, 1 M) is added dropwise, and the reaction is warmed to room temperature. After stirring 1 hour, the reaction is quenched with aq. citric acid, extracted DCM, dried MgSO 4 , filtered, and concentrated in-vacuo. The residue is purified by silica gel chromatography.
- FIG. 8A shows a general synthetic strategy to synthesize photoacid compounds of Formula (I) using a common precursor (ortho dihydroxyarene; 32).
- X′ and Y′ are linked together to form part of an arene or heteroarene.
- Compound 32 is then carried through the steps of Example 1 and/or Example 3 to provide compound 34, shown in FIG. 8A with an optional protecting group (PG; see [Ref 9] and [Ref 8]).
- PG optional protecting group
- FIG. 8B shows a general synthetic scheme for the synthesis of closed chain cyanines with a variable-length polyene and variable heteroaryl groups.
- commercially available precursors are converted to compounds 36 and 35 (which can be converted into compound 36), and compound 26 is converted into compound 37 (see, e.g. [Ref 21]).
- X is nitrogen and Y is a heteroatom such as, for example, N, O, or S.
- Groups R a and R b in compounds 35, 36, and 37 can be H, alkyl, or O-alkyl. In the alternative, R a and R b can be linked together to form part of an arene or heteroarene.
- R a and R b when R a and R b are linked together to form part of an arene or heteroarene, the arene or heteroarene can be of the form of compound 32 and can be carried through the steps of FIG. 8A .
- R a and R b when R a and R b are O-alkyl, they may be subjected to Deprotection conditions (see, e.g., synthesis of compound 8 in Example 3) to afford a dihydroxylated arene or heteroarene can be of the form of compound 32.
- FIG. 8C shows an exemplary application of the synthesis shown in FIG. 8B to the general synthesis of photoacid compounds with cyanine light absorbing moieties.
- compound 34 from FIG. 8A is carried through the synthetic steps of FIG. 8B (with a deprotection step; see [Ref 9] and [Ref 8]) to afford a photoacidic compound (29) as herein described with payload moiety R 3 .
- FIG. 8D shows a photoactive molecule with a particular desired absorbance wavelength (compound 40) and an analogous photoactive compound as herein described (compound 41) incorporating compound 40 as the light absorbing moiety.
- Compound 40 can be synthesized using the quinolinium 44 (analogous to compound 36) using the methods of FIG. 8B .
- the synthesis of quinolinium 44 can be accomplished using the reactions of FIG. 8E .
- FIG. 8F shows the synthesis of photoacid compound 41 according to the methods of FIG. 8A , FIG. 8B , and FIG. 8E .
- Compound 45 which can be synthesized in one step from a commercially available compound, is converted to dihydroxyquinoline 43 via the first reaction of FIG. 8E .
- Dihydroxyquinoline 43 can then be converted to compound 47 via the reactions of FIG. 8A .
- Compound 47 can then be converted to quinolinium 48 via the second reaction of FIG. 8E .
- Quinolinium 48 can in turn be converted to photoacid compound 41 via the last reaction of FIG. 8B similar to what is done in FIG. 8C .
- alkyl refers to a linear, branched, or cyclic saturated hydrocarbon group typically although not necessarily containing 1 to about 15 carbon atoms, or 1 to about 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, octyl, decyl, and the like, as well as cycloalkyl groups such as cyclopentyl, cyclohexyl and the like. Generally, although again not necessarily, alkyl groups herein contain 1 to about 15 carbon atoms.
- cycloalkyl intends a cyclic alkyl group, typically having 4 to 8, or 5 to 7, carbon atoms.
- substituted alkyl refers to alkyl substituted with one or more substituent groups
- heteroatom-containing alkyl and heteroalkyl refer to alkyl in which at least one carbon atom is replaced with a heteroatom. If not otherwise indicated, the terms “alkyl” and “lower alkyl” include linear, branched, cyclic, unsubstituted, substituted, and/or heteroatom-containing alkyl and lower alkyl, respectively.
- hydrocarbyl refers to any univalent radical, derived from a hydrocarbon, such as, for example, methyl or phenyl.
- hydrocarbylene refers to divalent groups formed by removing two hydrogen atoms from a hydrocarbon, the free valencies of which may or may not be engaged in a double bond, typically but not necessarily containing 1 to 20 carbon atoms, in particular 1 to 12 carbon atoms and more particularly 1 to 6 carbon atoms which includes but is not limited to linear cyclic, branched, saturated and unsaturated species, such as alkylene, alkenylene alkynylene and divalent aryl groups, e.g., 1,3-phenylene, —CH 2 CH 2 CH 2 -propane-1,3-diyl, —CH 2 -methylene, —CH ⁇ CH—CH ⁇ CH—.
- hydrocarbyl refers to univalent groups formed by removing a hydrogen atom from a hydrocarbon, typically but not necessarily containing 1 to 20 carbon atoms, in particular 1 to 12 carbon atoms and more particularly 1 to 6 carbon atoms, including but not limited to linear cyclic, branched, saturated and unsaturated species, such as univalent alkyl, alkenyl, alkynyl and aryl groups e.g. ethyl and phenyl groups.
- heteroatom-containing refers to a alkyl group in which one or more carbon atoms is replaced with an atom other than carbon, e.g., nitrogen, oxygen, sulfur, phosphorus or silicon, typically nitrogen, oxygen or sulfur.
- heteroalkyl refers to an alkyl substituent that is heteroatom-containing
- heterocyclic refers to a cyclic substituent that is heteroatom-containing
- heteroaryl and heteroteroaromatic respectively refer to “aryl” and “aromatic” substituents that are heteroatom-containing, and the like.
- heterocyclic group or compound may or may not be aromatic, and further that “heterocycles” may be monocyclic, bicyclic, or polycyclic as described above with respect to the term “aryl.”
- heteroalkyl groups include alkoxyaryl, alkylsulfanyl-substituted alkyl, N-alkylated amino alkyl, and the like.
- heteroaryl substituents include pyrrolyl, pyrrolidinyl, pyridinyl, quinolinyl, indolyl, pyrimidinyl, imidazolyl, 1,2,4-triazolyl, tetrazolyl, and others known to a skilled person, and examples of heteroatom-containing alicyclic groups are pyrrolidino, morpholino, piperazino, piperidino, and other known to a skilled person.
- alkoxy intends an alkyl group bound through a single, terminal ether linkage; that is, an “alkoxy” group may be represented as —O-alkyl where alkyl is as defined above.
- a “lower alkoxy” group intends an alkoxy group containing 1 to 6 carbon atoms.
- alkenyloxy and lower alkenyloxy respectively refer to an alkenyl and lower alkenyl group bound through a single, terminal ether linkage
- alkynyloxy and “lower alkynyloxy” respectively refer to an alkynyl and lower alkynyl group bound through a single, terminal ether linkage.
- alkylamino intends an alkyl group bound through a single terminal amine linkage; that is, an “alkylamino” may be represented as —NH-alkyl where alkyl is as defined above.
- a “lower alkylamino” intends a alkylamino group containing 1 to 6 carbon atoms.
- dialkylamino as used herein intends two identical or different bound through a common amine linkage; that is, a “dialkylamino” may be represented as —N(alkyl) 2 where alkyl is as defined above.
- a “lower dialkylamino” intends a alkylamino wherein each alkyl group contains 1 to 6 carbon atoms.
- alkenylamino “lower alkenylamino”, “alkynylamino”, and “lower alkynylamino” respectively refer to an alkenyl, lower alkenyl, alkynyl and lower alkynyl bound through a single terminal amine linkage; and “dialkenylamino”, “lower dialkenylamino”, “dialkynylamino”, “lower dialkynylamino” respectively refer to two identical alkenyl, lower alkenyl, alkynyl and lower alkynyl bound through a common amine linkage.
- alkenylalkynylamino “alkenylalkylamino”, and “alkynylalkylamino” respectively refer to alkenyl and alkynyl, alkenyl and alkyl, and alkynyl and alkyl groups bound through a common amine linkage.
- aryl refers to an aromatic substituent containing a single aromatic ring or multiple aromatic rings that are fused together, directly linked, or indirectly linked (such that the different aromatic rings are bound to a common group such as a methylene or ethylene moiety).
- Aryl groups can contain 5 to 24 carbon atoms, or aryl groups contain 5 to 14 carbon atoms.
- Exemplary aryl groups contain one aromatic ring or two fused or linked aromatic rings, e.g., phenyl, naphthyl, biphenyl, diphenylether, diphenylamine, benzophenone, and the like.
- Substituted aryl refers to an aryl moiety substituted with one or more substituent groups
- heteroatom-containing aryl and “heteroaryl” refer to aryl substituents in which at least one carbon atom is replaced with a heteroatom, as will be described in further detail infra.
- arene refers to an aromatic ring or multiple aromatic rings that are fused together.
- exemplary arenes include, for example, benzene, naphthalene, anthracene, and the like.
- heteroatom e.g. O, N, or S.
- exemplary heteroarenes include, for example, indole, benzimidazole, thiophene, benzthiazole, and the like.
- substituted arene and “substituted heteroarene”, as used herein, refer to arene and heteroarene molecules in which one or more of the carbons and/or heteroatoms are substituted with substituent groups.
- cyclic refers to alicyclic or aromatic groups that may or may not be substituted and/or heteroatom containing, and that may be monocyclic, bicyclic, or polycyclic.
- alicyclic is used in the conventional sense to refer to an aliphatic cyclic moiety, as opposed to an aromatic cyclic moiety, and may be monocyclic, bicyclic or polycyclic.
- halo halogen
- halide halogen
- substituted as in “substituted alkyl,” “substituted aryl,” and the like, is meant that in the, alkyl, aryl, or other moiety, at least one hydrogen atom bound to a carbon (or other) atom is replaced with one or more non-hydrogen substituents.
- substituents include, without limitation: functional groups such as halo, hydroxyl, sulfhydryl, C1-C24 alkoxy, C2-C24 alkenyloxy, C2-C24 alkynyloxy, C5-C24 aryloxy, C6-C24 aralkyloxy, C6-C24 alkaryloxy, acyl (including C2-C24 alkylcarbonyl (—CO-alkyl) and C6-C24 arylcarbonyl (—CO-aryl)), acyloxy (—O-acyl, including C2-C24 alkylcarbonyloxy (—O—CO-alkyl) and C6-C24 arylcarbonyloxy (—O—CO-aryl)), C2-C24 alkoxycarbonyl (—(CO)—O-alkyl), C6-C24 aryloxycarbonyl (—(CO)—O-aryl), halocarbonyl (—CO)—X where X is halo,
- C1-C12 alkyl and C1-C6 alkyl C2-C24 alkenyl (e.g. C2-C12 alkenyl and C2-C6 alkenyl), C2-C24 alkynyl (e.g. C2-C12 alkynyl and C2-C6 alkynyl), C5-C24 aryl (e.g. C5-C14 aryl), C6-C24 alkaryl (e.g. C6-C16 alkaryl), and C6-C24 aralkyl (e.g. C6-C16 aralkyl).
- C2-C24 alkenyl e.g. C2-C12 alkenyl and C2-C6 alkenyl
- C2-C24 alkynyl e.g. C2-C12 alkynyl and C2-C6 alkynyl
- C5-C24 aryl e.g. C5-C14 aryl
- C6-C24 alkaryl
- acyl refers to substituents having the formula —(CO)-alkyl, —(CO)-aryl, or —(CO)-aralkyl
- acyloxy refers to substituents having the formula —O(CO)-alkyl, —O(CO)-aryl, or —O(CO)-aralkyl, wherein “alkyl,” “aryl, and “aralkyl” are as defined above.
- alkaryl refers to an aryl group with an alkyl substituent
- aralkyl refers to an alkyl group with an aryl substituent, wherein “aryl” and “alkyl” are as defined above.
- alkaryl and aralkyl groups contain 6 to 24 carbon atoms, and particularly alkaryl and aralkyl groups contain 6 to 16 carbon atoms.
- Alkaryl groups include, for example, p-methylphenyl, 2,4-dimethylphenyl, p-cyclohexylphenyl, 2,7-dimethylnaphthyl, 7-cyclooctylnaphthyl, 3-ethyl-cyclopenta-1,4-diene, and the like.
- aralkyl groups include, without limitation, benzyl, 2-phenyl-ethyl, 3-phenyl-propyl, 4-phenyl-butyl, 5-phenyl-pentyl, 4-phenylcyclohexyl, 4-benzylcyclohexyl, 4-phenylcyclohexylmethyl, 4-benzylcyclohexylmethyl, and the like.
- alkaryloxy and aralkyloxy refer to substituents of the formula —OR wherein R is alkaryl or aralkyl, respectively, as just defined.
- Optional or “optionally” means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not according to the guidance provided in the present disclosure.
- the phrase “optionally substituted” means that a non-hydrogen substituent may or may not be present on a given atom, and, thus, the description includes structures wherein a non-hydrogen substituent is present and structures wherein a non-hydrogen substituent is not present.
- an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
- Combinations of substituents envisioned can be identified in view of the desired features of the compound in view of the present disclosure, and in view of the features that result in the formation of stable or chemically feasible compounds.
- stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Electromagnetism (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
A photoacid compound having a light absorbing moiety attaching a payload moiety through a linker, in which the linker comprises a geminal dialkyl linked to a carbonyl group attaching the payload moiety, and the linker is configured to present the carbonyl oxygen for reaction with a hydroxyl group presented on the light absorbing moiety in ortho position to the linker.
Description
- The present application claims priority to U.S. Provisional Application No. 61/568,046, entitled “Long Wavelength activation of bioactive compounds” filed on Dec. 7, 2011 with docket number CIT-6041-P, and is related to PCT application Ser. No. ______ entitled “Caged compound delivery and related compositions, methods and systems” filed on Dec. 7, 2012, with docket number P1130-PCT2, each of which is incorporated herein by reference in its entirety.
- The present disclosure relates to compounds capable to deliver a payload in a controlled fashion. In particular, the present disclosure relates to photoacid compounds and related compositions methods and systems.
- Molecular delivery has been a challenge in the field of molecule analysis, in particular when aimed at obtaining controlled delivery of analytes of interest to specific environments. Whether for chemical, biological or medical applications or for fundamental studies, several methods are commonly used for the delivery of various classes of compounds including biomaterials and biomolecules.
- Controlled delivery of targets to specific environments, e.g. delivery of pesticides, delivery of chemicals such as a fluorescent dye on a biological or non-biological system, such as specific cell types and/or tissues of individuals in vitro and/or in vivo is currently still challenging, especially when directed at providing controlled release of the target in a controllable conformation, typically associated to a biological or chemical activity.
- Described herein are photoacid compounds and related compositions, methods, and systems that in some embodiments permit the uncaging and release of a payload molecule upon irradiation with a suitable wavelength light.
- According to a first aspect, a photoacid compound is described. The photoacid compound comprises a light absorbing moiety attaching a payload moiety through a linker moiety. In the photoacid compound, the linker moiety comprises a geminal dialkyl moiety linked to an ester group having a carbonyl oxygen, the carbonyl group of the ester attaching the payload moiety. In the photoacid compound, the light absorbing moiety attaches the linker moiety in ortho position to a hydroxyl group and the linker is configured to present the carbonyl oxygen for reaction with the hydroxyl group.
- According to a second aspect, a photoacid compound is described, the photoacid having the general structure according to formula (I):
- wherein:
-
- R4 is a light-absorbing moiety presenting a hydroxyl group for interaction with the carbonyl oxygen of the R3(CO)O group, wherein the light-absorbing moiety is a substituted or unsubstituted polycyclic aromatic hydrocarbon, a substituted or unsubstituted closed chain cyanine, or a substituted or unsubstituted hemicyanine, and wherein the hydroxyl group is covalently bonded to the polycyclic aromatic hydrocarbon, the closed chain cyanine, or the hemicyanine, and the hydroxyl group is in a position ortho to X1;
- R3 is a payload moiety, wherein the payload moiety is a substituted or unsubstituted alkyl, aryl, heteroaryl, alkoxy, alkylamino, or dialkylamino moiety;
- X1 is independently selected from the group consisting of C and O;
- m is between 0 and 3; and
- R1 and R2 are independently C1-C6 alkyl groups, cycloalkyl, or substituted or unsubstituted hydrocarbylene groups wherein when R1 and R2 are substituted or unsubstituted hydrocarbylene R1 and R2 they are linked together to form a cyclic moiety.
- According to a third aspect, a method to deliver a compound is described, the method comprises providing a caged compound, the caged compound being caged as a payload moiety within the photoacid compound herein described and in particular with a photoacid compound of Formula (I), the photoacid compound being in a ground state in which the hydrogen substituted heteroatom presented on the light absorbing moiety of the photoacid compound has a ground state pKa. The method for uncaging the caged compound by irradiating the photoacid compound with light at a wavelength suitable to promote the photoacid compound to an excited state wherein the hydrogen substituted heteroatom presented on the light absorbing moiety of the photoacid compound has an excited state pKa lower than the ground state pKa.
- According to a fourth aspect, a system to deliver a compound is described, the system comprising at least two of: one or more photoacids compounds, and in particular one or more photoacid compounds of Formula (I) and a light source suitable to irradiate light at a suitable wavelength, for simultaneous, combined or sequential use in methods herein described.
- Photoacid compounds herein described and related compositions, methods and systems allow in several embodiments controlled release of a payload moiety in various chemical and biological environments. In particular, in several embodiments, photoacid compounds herein described and related compositions methods and systems allow controlled release of a payload moiety upon irradiation at a wavelength of at least about 750 nm or higher.
- Photoacid compounds herein described and related compositions, methods and systems can be used in connection with applications wherein controlled delivery of a compound is desired. Exemplary applications comprise applications in medical field, biological and chemical research, such as drug development, molecule studies, light-activated therapies and strategies for imaging biological systems.
- The details of one or more embodiments of the disclosure are set forth in the accompanying drawings and the description below. Other features and objects will be apparent from the description and drawings, and from the claims.
- The accompanying drawings, which are incorporated into and constitute a part of this specification, illustrate one or more embodiments of the present disclosure and, together with the description of example embodiments, serve to explain the principles and implementations of the disclosure.
-
FIG. 1 shows a schematic illustration of photoacid compounds herein described and of related methods and systems. In particularFIG. 1A shows a schematic representation of a method to uncage a drug comprised as a payload in photoacid compound wherein the light absorbing moiety is formed by a NIR absorber.FIG. 1B shows a known reaction scheme of uncaging of a water molecule in a photoacid after protonation of a hydroxyl group wherein the protonation is induced by the increase in acidity of the photoacidic hydrogen.FIG. 1C shows a schematic of the novel protonation of a carbonyl group in a linking moiety and subsequent uncaging of a payload moiety of a generic photoacid compound after irradiation of the light absorbing moiety with light resulting in an increase in the acidity of the photoacidic proton.FIG. 1D shows the uncaging of a particular photoacid compound by irradiation of the photoacid compound with light resulting in the release of hydrocinnamic acid.FIG. 1E shows a schematic structure of an exemplary generic photoacid compound with an acene light absorbing moiety in which expansion of the acene chromophores allows absorption of a longer wavelength light.FIG. 1F shows an exemplary photoacid compound as herein described with a retinal/carotene-type light absorbing moiety.FIG. 1G shows an exemplary photoacid compound as herein described with a cyanine-type light absorbing moiety.FIG. 1 H shows the uncaging of a particular photoacid compound by irradiation of the photoacid compound with light resulting in the release of γ-aminobutyric acid with concomitant decarboxylation to release CO2. -
FIG. 2 shows a schematic of a ring opening reaction of a fluorescein molecule that results in fluorescence. -
FIG. 3 shows a schematic of a synthetic scheme for the synthesis of photoacid compounds with a naphthol-based light absorbing moiety. -
FIG. 4 shows a schematic of a synthetic scheme for the synthesis of photoacid compounds with a cyanine-based light absorbing moiety. -
FIG. 5 shows a schematic of a synthetic scheme for the synthesis of photoacids with a cyanine-based light absorbing moiety. -
FIG. 6 shows LC-MS traces for an exemplary photoacid compound as herein described before and after irradiation with light to uncage the payload moiety. -
FIG. 7 shows a schematic of a synthetic scheme for the synthesis of a photoacid compound with X1 is C. -
FIG. 8 shows a schematic of general synthetic schemes for the synthesis of cyanine-based photoacid compounds as herein described.FIG. 8A shows a general synthetic strategy to synthesize photoacid compounds of Formula (I) using a common precursor (ortho dihydroxyarene; 32).FIG. 8B shows a general synthetic scheme for the synthesis of closed chain cyanines with a variable-length polyene and variable heteroaryl groups.FIG. 8C shows an exemplary application of the synthesis shown inFIG. 8B to the general synthesis of photoacid compounds with cyanine light absorbing moieties.FIG. 8D shows a photoactive molecule with a particular desired absorbance wavelength (compound 40) and an analogous photoactive compound as herein described (compound 41) incorporatingcompound 40 as the light absorbing moiety.FIG. 8E shows the synthesis of a quinolinium compound that can be used in the synthesis of cyanines.FIG. 8D shows a photoactive molecule with a particular desired absorbance wavelength (compound 40) and an analogous photoactive compound as herein described (compound 41) incorporatingcompound 40 as the light absorbing moiety. - Described herein are photoacid compounds and related compositions, methods, and systems that in some embodiments permit the uncaging and release of caged payload molecules upon irradiation with long wavelength light.
- The term “photoacid” as used herein refers to a compound that can be switched from a ground state to an excited state upon absorption of light, and that has an excited state acidity associated to the excited states higher than a ground state acidity associated to the ground state. The term “excited state” as used herein refers to an electronic state of a moiety in which the molecule has absorbed light energy and been promoted to a higher energy state. This process is referred to as “excitation.” The term “ground state” refers to the electronic state of a moiety in which the electrons are in their lowest energy molecular orbitals. In photoacid compounds, the excitation can be accomplished, for example, by irradiating a photoacid molecule with light of energy equal to the difference in energy between the ground state and the excited state. The energy of the light is determined by the wavelength of the light according the relationship E=hc/λ, where E is the energy of the photon, h is Plank's constant, and λ is the wavelength of the light. In particular, in some embodiments, the light used to effect the excitation is infrared or near infrared light.
- In particular, molecules that can undergo excitation to an excited state are typically molecules comprising systems of conjugated π bonds such as those present in polyaromatic (e.g. polycyclic aromatic hydrocarbons) and polyene (e.g. cyanine and carotene molecules) molecules. In particular, the energy required to excite a molecule such as a photoacid can be decreased, which results in light of longer wavelengths being able to excite the molecule, by increasing the size of the system of conjugated π bonds (see, e.g., [Ref 1]).
- Determination of the excited states for a certain compound and the related level of energy can be performed by a skilled person using methods and techniques identifiable by a skilled person. By way of example, the excited states can be determined by measuring the absorption spectrum of a compound and thus the wavelengths of light absorbed by the compound via spectrophotometry.
- In particular, a “photoacid” in the sense of the present disclosure typically comprises a light absorbing moiety presenting an hydrogen substituted heteroatom. A shift in acidity following light absorbance by the light absorbing moiety can be detected by detecting the pKa of a hydrogen substituted heteroatom which is presented on the light absorbing moiety of the photoacid. Detection of the pKa of the hydrogen substituted heteroatom can be performed according to techniques and methods identifiable by a skilled person (see e.g. [Ref 2] and [Ref 3]). Exemplary photoacids include hydroxyaryls such as 2-naphthol which displays a ground state pKa of 9.5 and an excited state pKa (pKa*) of 2.8 (see, e.g., [Ref 4]). The pKa* of a photoacid can be determined, for example, by combining the Förster cycle with the pKa of the photo acid in its ground state to perform calculations known to those in the art, as well as by fluorescence titrations (see, e.g., [Ref 2] and [Ref 3]).
- In embodiments herein described, the photoacid compound of the disclosure comprise a light absorbing moiety which is attached to a payload moiety through a linker comprising a geminal dialkyl moiety which presents a carbonyl group attaching the payload moiety. In particular, in photoacid compounds of the disclosure the linker is configured to present the carbonyl oxygen in proximity to the hydroxyl of the light absorbing moiety and is further configured such that the hydroxy is ortho to the linker.
- The term “attach” or “attached” as used herein, refers to connecting or uniting by a covalent bond in order to keep two or more components together, which encompasses either direct or indirect attachment where, for example, a first moiety is directly bound to a second moiety, or one or more intermediate moieties are disposed between the first moiety and the second moiety.
- The term “present” as used herein with reference to a compound or functional group indicates attachment performed to maintain the chemical reactivity of the compound or functional group as attached. Accordingly, for example a carbonyl group presented on a linker, is able to perform under the appropriate conditions the one or more chemical reactions that chemically characterize the carbonyl group. The wording “present for reaction”, with reference to a compound or a functional group indicates attachment performed to maintain the chemical reactivity of the compound or functional group as attached, such that the attachment is performed in a configuration that allow the specific reaction mentioned. Accordingly, a carbonyl group presented for reaction with an hydroxyl group indicates a configuration in which the carbonyl group is in a position allowing a chemical reaction with the hydroxyl group.
- The term “light absorbing moiety” as used herein indicates moiety that is converted to an excited states upon absorption of light at a predetermined wavelength. Exemplary light absorbing moieties comprise long wavelength absorbing moieties (LWAP) able to absorb light at a wavelength greater than or equal to 750 nm, and more particularly a wavelength in a range from about 900 to about 1100 nm. Additional exemplary light absorbing moieties comprise short wavelength light absorbing moieties (SWAP) able to absorb light at a wavelength less than 750 nm and in particular at a wavelength from about 500 nm to about 750 nm and a wavelength from about 600 nm to about 750 nm.
- In some embodiments, the light absorbing moiety comprises a substituted or unsubstituted polycyclic aromatic hydrocarbon or substituted or unsubstituted closed chain cyanine or hemicyanine dye presenting a hydroxyl group in which the hydroxyl group is covalently bound to the substituted or unsubstituted polycyclic aromatic hydrocarbon or substituted or unsubstituted closed chain cyanine or hemicyanine dye. In particular, in some embodiments, the hydroxyl group can be covalently bound to a carbon of the substituted or unsubstituted polycyclic aromatic hydrocarbon or substituted or unsubstituted closed chain cyanine or hemicyanine dye such that the hydroxyl is ortho to the linker herein described.
- The term “linker” as used herein indicates to an organic structure configured to connect two moieties to form a stable chemical structure. In particular, linker in the sense of the present disclosure can be formed by a mono or dialkoxy moiety comprising the dialkyl germinal group and presenting the carbonyl group for reaction.
- The term “payload” as used herein refers to a moiety carried by a compound in a configuration that allows the relevant delivery under controllable parameters. In particular, in embodiments herein described a payload is a moiety is connected to the linker and forms part of the photoacidic compounds herein described. In particular in embodiments herein a payload indicates an organic moiety configured to attach the carbonyl group of the linker of a photoacid compound herein described.
- In particular, in some embodiments, a photoacid compound herein described has of the general structure according to Formula (I):
- wherein:
-
- R4 is a light-absorbing moiety presenting a hydroxyl group for interaction with the carbonyl oxygen of the R3(CO)O group, wherein the light-absorbing moiety is a substituted or unsubstituted polycyclic aromatic hydrocarbon, a substituted or unsubstituted closed chain cyanine, or a substituted or unsubstituted hemicyanine, and wherein the hydroxyl group is covalently bonded to the polycyclic aromatic hydrocarbon, the closed chain cyanine, or the hemicyanine, and the hydroxyl group being in a position ortho to X1;
- R3 is a payload moiety, wherein the payload moiety is a substituted or unsubstituted alkyl, aryl, heteroaryl, alkoxy, alkylamino, or dialkylamino moiety; and
- X1 is independently selected from the group consisting of C and O;
- m is between 0 and 3; and
- R1 and R2 are independently C1-C6 alkyl groups, cycloalkyl, or substituted or unsubstituted hydrocarbylene groups wherein when R1 and R2 are substituted or unsubstituted hydrocarbylene groups they are linked together to form a cyclic moiety.
- In particular, in the photoacid compound of formula (I) and other embodiments herein described, the moiety of Formula (II)
- is the linker.
- In particular, in some embodiments, R4 can be a moiety of Formula (III):
- wherein n is between 0 and 5.
- In particular, in some, R4 can be a moiety of Formula (IV):
- where n is between 0 and 5, and m is between 1 and 3.
- In particular, in some embodiments, R4 can be a moiety of Formula (V):
- wherein Ra and Rb are independently H, alkyl, or O-alkyl; Y is N, O, or S; and p is between 1 and 4.
- In particular, in some embodiments, R4 can be a moiety of Formula (VI):
- wherein Rc and Rd are independently alkyl and q is between 1 and 4.
- In particular, in some embodiments, R4 can be a moiety of Formula (VII):
- wherein r is between 1 and 4.
- In particular, in some embodiments, R4 can be a moiety of Formula (VIII):
- A skilled person will understand, upon a reading of the present disclosure, that the light absorbing moiety and herein described can be substituted or unsubstituted and in particular have additional substituents which can be added to impart additional functionalities such as, for example, hydrophilic substituents (e.g. sulfonate, and in particular polysulfonates such as polysulfonate peptides or oligopeptides, as well as polyethylene glycol groups), and functional groups and/or moieties to connect the photoacid compounds herein described to other molecules and/or substances (e.g. for connection to carbon nanotubes, fullerenes, antibodies, polymers, proteins, lipids, carbohydrates, and others identifiable to a skilled person).
- In embodiments herein described the photoacid attaches a payload and in particular a payload R3 in a photoacid of Formula (I).
- In particular, R3 can be an organic moiety such as, for example a substituted or unsubstituted alkyl, aryl, heteroaryl, alkoxy, alkylamino, or dialkylamino moiety. In some embodiments, and in particular in embodiments where R3 is a substituted or unsubstituted alkyl, aryl, heteroaryl molecule, R3 is adapted to exist in a carboxylic acid form wherein the carboxylic acid form can be used to provide the carbonyl group of the linker of Formula (II) (see Example 1 and Example 3).
- In particular, in some embodiments, R3 can be a moiety of Formula (IX):
- wherein q is between 0 and 5, Rα is H, or substituted or unsubstituted alkyl, alkylamino, alkoxy, aryl, arylamino, aryloxy, heteroaryl, hetroarylamino, and heteroaryloxy; X is C or N; and wherein when q is greater than 1, each R′ is independent of the other Rα substituents.
- In particular, in some embodiments wherein R3 is according to Formula (IX), R3 can be selected from the group consisting of Formulas (X)-(XII):
- In particular, in some embodiments, R3 can be a moiety of Formula (XIII):
- wherein n is between 1 and 5, Rα, Rβ, and Rγ are independently H, or substituted or unsubstituted alkyl, alkylamino, alkoxy, aryl, arylamino, aryloxy, heteroaryl, hetroarylamino, and heteroaryloxy; and wherein when n is greater than 1, the Rα and Rβ of each C(Rα)(Rβ) unit are independent of the Rα and Rβ of the other units.
- In particular, in some embodiments wherein R3 is according to Formula (XIII), R3 can be selected from the group consisting of Formulas (XIV) and (XV):
- In particular, in some embodiments, R3 can be a moiety of Formula (XVI):
- wherein p is between 1 and 5, Rα, Rβ, and Rγ are independently H, or substituted or unsubstituted alkyl, alkylamino, alkoxy, aryl, arylamino, aryloxy, heteroaryl, hetroarylamino, and heteroaryloxy; wherein Rδ is H, substituted or unsubstituted alkyl, acyl, aryl; and wherein when p is greater than 1, the Rα and Rβ of each C(Rα)(Rβ) unit are independent of the Rα and Rβ of the other units.
- In particular, in some embodiments wherein R3 is according to Formula (XVI), R3 can be of Formula (XVII):
- In particular, in some embodiments wherein R3 is according to Formula (XVI) and Rδ is acyl, R3 can be a peptide or oligopeptide such that the peptide or oligopeptide is attached to the linker via the N-terminus of the peptide or oligopeptide.
- In particular, in some embodiments, R3 can be a moiety of Formula (XVIII):
- wherein m is between 1 and 5, Rα, Rβ, and Rγ are independently H, or substituted or unsubstituted alkyl, alkylamino, alkoxy, aryl, arylamino, aryloxy, heteroaryl, hetroarylamino, and heteroaryloxy; and wherein when m is greater than 1, the Rα and Rβ of each C(Rα)(Rβ) unit are independent of the Rα and Rβ of the other units.
- In particular, in some embodiments, R3 can be a moiety of Formula (XIX):
- wherein q is between 0 and 4, Rα is H, or substituted or unsubstituted alkyl, alkylamino, alkoxy, aryl, arylamino, aryloxy, heteroaryl, hetroarylamino, and heteroaryloxy; c is a substituted or unsubstituted hydrocarbylene, X is C or N; and wherein when q is greater than 1, each Rα is independent of the other Rα substituents.
- In some embodiments, the payload moiety and in particular the payload molecule R3 is a molecule for which controlled disconnection and release from the photoacid compound is desired. Exemplary payload molecules include imaging agents, drug molecules, fluorescent dyes, pesticides, pigments, neurotransmitter; anti-cancer agents; sedatives; antibodies; protein therapeutics and others identifiable to a skilled person upon a reading of the present disclosure.
- In some embodiments herein described the payload R3 can be attached to R4 through the linker of formula (II). In particular in the linker of formula (II), X1 can be independently O or C.
- In some embodiments, R1 and R2 are methyl groups or other C1-C6 alkyl groups or cycloalkyl. In other embodiments, R1 and R2 are linked to form a cyclic moiety such as a cyclopentyl or cyclohexyl moiety.
- In particular, in some embodiments, the light absorbing moiety R4 is a moiety according to Formula (III); and the linker is a linker of Formula (II) wherein X1 is O and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety. In particular, in other embodiments the light absorbing moiety R4 is a moiety according to Formula (III), the linker is a linker of Formula (II) wherein X1 is C and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- In particular, in some embodiments, the light absorbing moiety R4 is a moiety according to Formula (III) wherein n is 0; and the linker is a linker of Formula (II) wherein X1 is O and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety. In particular, in other embodiments the light absorbing moiety R4 is a moiety according to Formula (III) wherein n is 0, the linker is a linker of Formula (II) wherein X1 is C and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- In particular, in some embodiments, the light absorbing moiety R4 is a moiety according to Formula (IV); and the linker is a linker of Formula (II) wherein X1 is O and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety. In particular, in other embodiments, the light absorbing moiety R4 is a moiety according to Formula (IV); and the linker is a linker of Formula (II) wherein X1 is C and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety
- In particular, in some embodiments, the light absorbing moiety R4 is a moiety according to Formula (IV) wherein m is 2 and n is 0; and the linker is a linker of Formula (II) wherein X1 is O and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety. In particular, in other embodiments, the light absorbing moiety R4 is a moiety according to Formula (IV) wherein m is 2 and n is 0; and the linker is a linker of Formula (II) wherein X1 is C and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- In particular, in some embodiments, the light absorbing moiety R4 is a moiety according to Formula (V); and the linker is a linker of Formula (II) wherein X1 is 0 and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety. In particular, in other embodiments, the light absorbing moiety R4 is a moiety according to Formula (V); and the linker is a linker of Formula (II) wherein X1 is C and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- In particular, in some embodiments, the light absorbing moiety R4 is a moiety according to Formula (VI), and the linker is a linker of Formula (II) wherein X1 is O and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety. In particular, in other embodiments, the light absorbing moiety R4 is a moiety according to Formula (VI); and the linker is a linker of Formula (II) wherein X1 is C and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- In particular, in some embodiments, the light absorbing moiety R4 is a moiety according to Formula (VI) wherein q is 2, and the linker is a linker of Formula (II) wherein X1 is O and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety. In particular, in other embodiments, the light absorbing moiety R4 is a moiety according to Formula (VI) wherein q is 2; and the linker is a linker of Formula (II) wherein X1 is C and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- In particular, in some embodiments, the light absorbing moiety R4 is a moiety according to Formula (VII), and the linker is a linker of Formula (II) wherein X1 is O and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety. In particular, in other embodiments, the light absorbing moiety R4 is a moiety according to Formula (VII); and the linker is a linker of Formula (II) wherein X1 is C and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- In particular, in some embodiments, the light absorbing moiety R4 is a moiety according to Formula (VII) wherein r is 2, and the linker is a linker of Formula (II) wherein X1 is O and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety. In particular, in other embodiments, the light absorbing moiety R4 is a moiety according to Formula (VII) wherein r is 2; and the linker is a linker of Formula (II) wherein X1 is C and R1 and R2 are methyl, ethyl, or linked together to form a cyclopentyl or cyclohexyl moiety.
- In particular, in some embodiments, one or more hydrophilic substituent that can be added to the light absorbing moiety and/or can be comprised in the payload moiety to provide or increase a desired water solubility.
- In embodiments herein described, the photoacid compounds of the disclosure can be used in methods and systems to deliver the payload R3 in a controlled fashion.
- In particular, a payload R3 can be released or decaged by providing the light absorbing moiety of the photoacid with a wavelength suitable to switch the state of the light absorbing moiety R4 from a ground state to an excited state.
- The term “cage” as used herein relates to the interaction between a first chemical moiety and a second chemical moiety that minimizes the participation in physical chemical or biological reactions of the second chemical moiety. In particular, the payload is caged by the linker moiety through covalent bond of the carbonyl group of the linker with a suitable functional group in the linker. The terms “decage” or “uncage” herein are defined as a modification of a caging interaction between a first and second chemical moiety to the chemical moiety, forming liberating the second molecule to participate in chemical or biological reactions. In embodiments herein described, decaging is performed through cleavage of the covalent bond between carbonyl group and the payload. Decaging of a compound can be detected by identifying the decaged activity of the uncaged compound or by LC-MS spectroscopy to identify either the caged compound, the first moiety, or the second moiety.
- Determination of a suitable wavelength to perform the switching from a ground state to an excited state can be performed by a skilled person based on the structural and chemical properties of the light absorbing moiety. For example, in some embodiments, a suitable wavelength can be selected based on known photoactive molecules (e.g. polycyclic aromatic hydrocarbons and/or cyanine; see, e.g., [Ref 1]) which can then be subjected to the appropriate preparation methods exemplified in Examples 1-4 and Examples 7-8.
- In embodiments of photoacids of the present disclosure, the wavelength is selected so that the promotion of the light absorbing moiety R4 from a ground state to an excited state results in a decrease of the pKa of the photoacidic R4OH group relative to the pKa of the same OH group in the ground state. The consequent shifting of the acid base equilibrium of the photoacid results in the release of payload R3. Accordingly, detection of the successful switching to an excited state by the light absorbing moiety R4 following irradiation of the photoacids with a suitable wavelength can be performed by detecting a switching in acidity in the reaction solution performed by measuring pKa of the photoacidic R4 hydroxyl group.
- Accordingly, according to methods and systems herein described, providing a caged compound can be performed by synthesizing a photoacid of Formula (I) including the compound caged as a payload moiety. The photoacid compound is selected to have a light absorbing moiety with a OH group such that upon irradiation with light at a wavelength exciting the light absorbing moiety the pKa of the OH group is lowered.
- In some embodiments, the light absorbing moiety can be formed by a LWAP which is promoted to an excited state upon irradiation with an infrared light or a near infrared light (or NIR). The term “infrared light” as used herein refers to light in the infrared region of the electromagnetic spectrum from approximately 0.75 μm to 1000 μm. The term “near infrared” refers to a region of the infrared spectrum from approximately 0.75 μm (750 nm) to 1.4 μm (1400 nm).
- In this connection, reference is made to the schematic illustration of
FIG. 1 in which theFIG. 1A presents a schematic illustration of a light activated photoacid releasing according to the present disclosure, where a long-wavelength absorber is linked to the exemplary payload moiety formed by a drug, the drug being replaceable by an imaging agent or other payload molecule as will be understood by a skilled person.FIG. 1B shows a UV-activated photoacid releasing water, through photoactive protonation of an hydroxyl alcohol presented by a naphthyl moiety resulting in the release of water to be considered in comparison withFIG. 1C showing an exemplary light activated photoacid releasing according to the present disclosure in which the light absorbing moiety is a napthol. InFIG. 1C , the system is designed to have a photoacidic group (the OH), and an ester that can intramolecularly hydrogen bond to the OH. InFIG. 1C , excitation with light can increase the acidity of the OH, and a proton transfer occurs. In the illustration ofFIG. 1C , the ester is a derivative of a t-butyl ester, a class that is especially sensitive to acid-catalyzed ester cleavage. t-Butyl esters suitable for inclusion in a linker herein described comprise t-butyl esters commonly used in commercial solid phase peptide synthesizers and t-butyl esters that are part of the common Boc protecting group. In particular, in several suitable t-butyl esters, the standard t-butyl cleavage mechanism can produce a generic carboxylate. In the illustration ofFIG. 1C , cleavage in this system releases the generic entity RCO2H, a carboxylic acid, which, under physiological conditions will be in its deprotonated, carboxylate form (structure in box). Computational studies show that the intramolecular hydrogen bond shown inFIG. 1C is viable. - In some compounds herein described, the photochemical excited state can increase the acidity of appropriate groups by as many as 10 orders of magnitude ([Ref 5] and [Ref 6]). Such an increase in acidity is intramolecular and hence usually does not alter the pH of the surrounding environment. In some embodiments, the shift in acidity (pKa) of about 10 orders of magnitude is corresponds to only an energy change of <14 kcal/mol, which supports the conclusion that suitable light absorbing moiety for the photoacid compounds herein described can absorb a very long wavelength light (e.g. from about 900 to about 1100 nm) and that various moiety that can be excited at long wavelength are expected to be able to initiate photoacid chemistry. For example, light at 1010 nm has an energy of 28 kcal/mol, twice what is needed to produce the desired pKa shift.
-
FIG. 1D shows a proof of concept establishing viability of the essential photochemical reaction proposed (see also Example 5 showing that irradiation produces the carboxylic acid shown).FIG. 1E shows how the light-absorbing feature of the molecule—the chromophore—can be varied while leaving the essential chemistry intact. As the chromophore gets larger, it can absorb longer wavelength light such as, for example, long wavelength visible light and/or NIR light. Even at wavelengths far out into the NIR, enough energy can be present to enhance the pKa of the OH. For example, light at 1010 nm (commonly used in optical coherence tomography) has an energy of 28 kcal/mol, twice what is needed or a factor of 10 orders of magnitude. - The light absorbing moieties described herein can be selected to absorb longer wavelengths of light. In some instances, known dyes and NIR absorbers, can permit empirical determination which systems are most effective (see, for example, [Ref 1]).
FIG. 1F shows a retinal/carotene-type compound that can be continuously tuned by just increasing the number of double bonds. In this approach, the molecule left after uncaging resembles carotene or vitamin E, and can exert non-toxic activity.FIG. 1G shows a merocyanine dye strategy. These are very common, highly tunable structures that have seen extensive biological use in the form of the common Cy and Alexa dyes ([Ref 7]) and possess arene and heteroarene moieties suitable to the preparation reactions of Examples 1-4 and Examples 7-8. - The photochemistry illustrated by the exemplary illustration of
FIG. 1 can uncage compounds other than carboxylates.FIG. 1H shows uncaging of an amine, in this particular case producing the inhibitory neurotransmitter γ-aminobutyric acid (GABA). This strategy can be used to uncage many compounds including, for example, neurotransmitters, anti-cancer agents, sedatives, antibodies, protein therapeutics, imaging markers, and others. By way of example, a compound such as etomidate can be caged in several ways. The unfunctionalized N of the imidazole ring of etomidate can be acylated to produce a structure that can be acid cleaved. Alternative, carboxyl derivatives at C2 of etomidate (between the two nitrogens) decarboxylate when hydrolyzed, feeding naturally into the t-butyl ester strategy herein described. From the structure shown above, the unfunctionalized N of the imidazole ring of etomidate provides a handle for attaching a photocage. - The generality of the uncaging process herein described can permit the develop other probes and ways to monitor the efficiency of the system. For example, fluorescein is a common dye that is often used in biological imaging. It exists in two forms that can interconvert (
FIG. 2 ). Either the carboxylic acid or the OH of the fluorescein could be caged within the photoacid compounds described herein. The caged compound would not be fluorescent. Photonic uncaging would liberate fluorescein, allowing an array of imaging strategies to evaluate the efficiency and localization of the photonic uncaging. Of course, many other dyes and imaging agents could be manipulated in the same way. - In embodiments of the photoacid compounds herein described, the photochemical excited state can increase the acidity of appropriate groups by as many as 10 orders of magnitude ([Ref 5] and [Ref 6]). In those embodiments, such an increase in acidity is intramolecular and hence does not alter the pH of the surrounding environment.
- In some embodiments, a suitable wavelength provides an energy change of <14 kcal/mol and results in shifting an acid-base equilibrium (pKa) by 10 orders of magnitude. In particular in some embodiments, such a shift is associated to a wavelength of from about 900 to about 1100 nm). For example, light at 1010 nm has an energy of 28 kcal/mol, twice what is needed to produce the desired pKa shift. Additional embodiments will be identifiable to a skilled person upon reading of the present disclosure.
- In some embodiments, the photoacids are expected to be tunable with regard to lifetime and absorption spectrum. Often, the excited-state lifetimes of these molecules are short, which could limit the efficiency of the proton-transfer reaction. However, several strategies for enhancing excited state lifetimes are known, including adding heavy atoms to facilitate conversion to the longer-lived triplet excited state. Additionally, the addition of electron-withdrawing substituents at key points in the extended π system can create “super photoacids” which deprotonate very efficiently in aqueous solutions upon excitation. In some embodiments, photoacidic molecules can be based on 2-naphthols, which display the desired photoacid effect, have a good safety profile, and can be easily modified to control water-solubility and to the tune the optical properties (see e.g. schematized in
FIG. 1C andFIG. 1D ). - In some embodiments, the long wavelength light used to uncage the payload is infrared light. In particular, in some embodiments, the infrared light is of a wavelength between 750 nm and 1400 nm corresponding to near infrared light. In other embodiments the near infrared light used to uncage the payload compounds can be between 900 and 1100 nm.
- The method for and uncaging the caged compound by irradiating the photoacid compound of Formula (I) with light at a wavelength suitable to promote the photoacid compound of Formula (I) to an excited state wherein the hydrogen substituted heteroatom presented on the light absorbing moiety of the photoacid compound has an excited state pKa lower than the ground state pKa.
- Irradiating can be performed through various procedures and techniques identifiable by a skilled person. In particular, a long wavelength light can be delivered by any of a number of means such as via microscope, endoscope, LCD panel or LED display as handheld or non-portable devices or worn as glasses or other such attachment to the body. Image intensifiers can be used to further increase the emitted power from such devices in order to activate the preparation of molecules.
- Other approaches can use high intensity short wavelength light and are suitable for applications in which use of the short length is desired. For example in a biological environment, use of a high intensity short wavelength can be used in application wherein production of reactive oxygen species or genetic manipulation of host cells is desired.
- Photoacid compounds described herein can be provided as a part of systems to deliver compounds, identifiable by a skilled person upon reading of the present disclosure. In some embodiments, the systems for delivery of the caged compounds herein described can be provided in the form of combinations of photoacid compounds and/or related compositions, in which the system can comprise one or more photoacid compounds, and a suitable vehicle identifiable by a skilled person.
- In some embodiments, the systems herein described can be provided in the form of kits of parts. In a kit of parts, one or more photoacid compounds herein described, and suitable light source and other reagents to perform the reactions can be comprised in the kit independently. The photoacid compounds can be included in one or more compositions, and each photoacid compounds can be in a composition together with a suitable vehicle.
- The term “vehicle” as used herein indicates any of various media acting usually as solvents, carriers, binders or diluents for the caged compounds that are comprised in the composition as an active ingredient.
- Further characteristics of the present disclosure will become more apparent hereinafter from the following detailed disclosure by way or illustration only with reference to an experimental section.
- The photoacid compounds, compositions methods and systems herein described are further illustrated in the following examples, which are provided by way of illustration and are not intended to be limiting.
- In particular, the following examples illustrate exemplary photoacid in which the light absorbing moiety is formed by naphthol, and cyanine, X1 is an 0 or a C, R1 and R2 are either methyl or are linked to form a cycloalkyl moiety and the payload hydrocinnamic acid and related methods and systems. A person skilled in the art will appreciate the applicability and the necessary modifications to adapt the features described in detail in the present section, to additional photoacid compounds, methods and systems according to embodiments of the present disclosure.
- A skilled person will realize, upon a reading of the present disclosure, that compounds similar to those exemplified below can be made using the synthetic methods herein described. A skilled person can select suitable starting material based on the starting materials exemplified below by utilizing databases such as SCIFINDER® and REAXYS®. A skilled person would also be able to use purification methods in addition to those exemplified below such as, for example, recrystallization, preparatory thin-layer chromatograph, preparatory high-pressure liquid chromatography, and others known in the art. A skilled person will also realize, that where appropriate, protecting groups for functional groups can be used according to methods known in the art (see, e.g. [Ref 8] and [Ref 9])
- Described below is the synthesis of
compound 1, as seen inFIG. 3 . -
- To a 0.1 M solution of 3,4-dihydroxynaphthalene (2) in dry dichloromethane (DCM) under argon is added at 0° C. 2.8 eq triethylamine (TEA) followed by chloroacetyl chloride (1.1 eq). The solution is allowed to warm to room temperature over one hour, then refluxed four hours. Upon completion, the reaction is diluted with water, and extracted with DCM. The combined organics are washed with brine, dried, filtered and concentrated in-vacuo to afford the product (3).
- A skilled person will realize that other chloroacyl chlorides can be selected to increase the ring size of the lactone thereby being able to produce different values of n in the photoacid compounds of Formula (I). By way of example, 3-chloropropionyl chloride and 4-chlorobutyryl chloride can be used in place of chloroacetyl chloride to provide photoacid compounds of Formula (I) with values of n of 2 and 3, respectively.
- A skilled person will also realize that the above reaction is not limited to 3,4-dihydroxynaphthalene and that the above strategy can be applied to other ortho dihydroxyaryl and heteroaryl molecules to provide light absorbing moieties with different functional groups on the light absorbing moiety.
- A skilled person will also realize that hydroxyl groups can be placed on an arene or heteroarene using methods known to a skilled person (e.g. aromatic substitution reactions). By way of example, an aryl or heteroaryl ring can be subjected to nitration/reduction reactions to afford ortho diamino aryl or heteroaryl rings which can then be subjected to the Sandmeyer reaction (see, e.g. [Ref 10]) using water to convert the amino groups into hydroxyl groups to afford ortho dihydroxy aryl and heteroaryl molecules.
-
-
Lactone 3 is dissolved in dry tetrahydrofuran (THF; 0.2 M) under argon and cooled to 0° C. Methylmagnesium bromide (MeMgBr; 2.2 eq, 3.0 M in diethyl ether) is added dropwise and the reaction is allowed to warm to room temperature. After one hour, a solution of hydrocinnamoyl chloride (2.2 eq) in dichloromethane is added dropwise, and the mixture is stirred overnight. Upon completion, the reaction is quenched with saturated aqueous sodium bicarbonate, and extracted with dichloromethane. The combined organics are dried over MgSO4, filtered and concentrated in-vacuo. The crude is flashed on silica-gel eluting with 10% ethyl acetate (EtOAc) in hexane to yield the product (4) as a crude oil. - A skilled person would recognize that additional Grignard reagents can be chosen such that groups other than methyl can be substituted in the positions corresponding to R1 and R2 in Formulas (I)-(II) described herein. A skilled person would also recognize that a bis-Grignard reagent could be used to synthesize a compound in which R1 and R2 are they are linked together to form a cyclic moiety. Such an exemplary reaction is:
- and an exemplary procedure would be as follows [Ref 11]: to a solution of magnesium turnings (10 eq) in dry THF, 1,4-dibromobutane (2.2 eq, 0.2 M) is added and the solution is gently heated until reaction is initiated. After 1 hour, the solution is transferred via cannula into a stirred solution of 25 (1.0 eq, 0.2 M) in dry THF under Ar at 0° C. The reaction is allowed to warm to room temperature over 1 hour. To the solution is then added the acid chloride (2.2 eq, 0.2 M) as a solution in DCM. The mixture is stirred at room temperature overnight, then quenched with water. The mixture is extracted with DCM, and the combined organics are dried with MgSO4, filtered and concentrated in-vacuo. The resulting residue is taken up in 1:1 THF-MeOH, and cooled to 0° C. Aqueous LiOH (3 eq, 1 M) is added dropwise, and the reaction is warmed to room temperature. After stirring 1 hour, the reaction is quenched with aq. citric acid, extracted DCM, dried MgSO4, filtered, and concentrated in-vacuo. The residue is purified by silica gel chromatography.
- Additionally a skilled person would recognize that the acid chloride used in the reaction can comprise the payload compound (R3) and that payload compounds other than the phenylethyl payload of
compound 4a can be incorporated by choice of the appropriate acid chloride. A skilled person will also recognize that acid anhydrides, activated esters, and other activated carboxylic acid derivatives can be used instead of an acid chloride. -
- Diester 4 (0.1 M) is dissolved in 1:1 THF-methanol (MeOH) and cooled to 0° C. An aqueous solution of LiOH (3.0 eq, 1.0 M) is added dropwise and the reaction is warmed to room temperature. After 2.5 hours, the reaction is quenched with aqueous citric acid, and extracted with dichloromethane. The combined organics are dried over MgSO4, filtered and concentrated in-vacuo. The crude is flashed on silica-gel eluting with 20% EtOAc in hexane to yield the product (1) as a clear oil.
- A skilled person would recognize that the synthesis of the naphthalene-based photoacid compound 1 in Example 1 can be modified to synthesize acene-based photoacid compounds with more than two fused aryl rings. For example, a skilled person could apply the methods of Lin et al. (“Iterative synthesis of acenes via homo-elongation” Chem. Commun. 2009(7): 803-805) to perform the reaction:
- to provide an acene of desired length analogous to
compound 2 in Example 1, which could then be carried through the synthetic steps of Example 1. A skilled person would also recognize that the aldehyde and/or nitrile groups (R) in compound c can be converted to other functional groups (e.g. alcohols, esters, amines, and others identifiable to a skilled person) for use in functionalizing the final photoacid compound product though standard reaction conditions known to a skilled person (e.g. reduction with lithium aluminum hydride, diisobutyl aluminum hydride, and others identifiable to a skilled person). - A skilled person will also realize that the aldehyde groups (R) can be further converted into amines (e.g., by reductive amination; see, e.g., [Ref 12]). The amines can further be functionalized by standard peptide coupling techniques (see e.g. [Ref 13]) with sulfonate peptides such as, for example:
- to, for example, increase water solubility (see e.g., [Ref 14] and [Ref 15]).
- In in some embodiments, the substituent of compound 49 can be added to a pendent functional group (e.g. an amine) on the light absorbing moiety (see Examples 1-4). In particular, such a substituent can provide, for example, a compound according to Formula (XX):
- wherein R is CH2NH2 or another moiety according such as 49, and n is between 0 and 5; or a compound according to Formula (XXI):
- Described below is the synthesis of
photoacid compound 5 as shown inFIG. 5 . Synthesis ofcompound 7 - 3,4-dimethoxyaniline (6; 0.1 M) is dissolved in 1:1 HCl—H2O and cooled to −10° C. under argon. A chilled aqueous solution of NaNO2 (1.1 eq) is added slowly via syringe, ensuring that the reaction maintains a temperature below 0° C. After stirring 30 minutes, a chilled solution of 5 nCl2 (3 eq, 2.0 M) in concentrated HCl followed by 3-methyl-2-butanone (3 eq) is added. The mixture is stirred 30 minutes, then quenched into a vigorously stirred solution of aqueous sodium bicarbonate and EtOAc. After extraction with EtOAc, the combined organics are dried with MgSO4, filtered, and concentrated in-vacuo. The residue is taken up in AcOH (0.1 M), and additional 3-methyl-2-butanone (3 eq) is added. The reaction is stirred overnight at room temperature, then concentrated in-vacuo. The crude is flashed directly on silica-gel eluting with 75% EtOAc in hexane to obtain the product (7) as a brown oil.
-
- Dimethoxyindolenine 7 (0.1 M) is dissolved in dry DCM under argon, and cooled to 0° C. BBr3 (2.2 eq) is added dropwise, and the mixture is allowed to warm to r.t. After stirring 3 hours, the reaction is diluted in water, and adjusted to
pH 5 using solid sodium acetate. The mixture is extracted with DCM, and the combined organics are dried over Na2SO4, filtered, and concentrated in-vacuo. The residue is flashed on 5% MeOH in DCM with 1% acetic acid to obtain the desired product (8) as a brown solid. -
- To a solution of 8 in dry DCM (1 eq, 0.1 M) under argon is added at 0° C. triethylamine (2.2 eq) followed by chloroacetylchloride (1.1 eq). The solution is allowed to warm to room temperature over one hour, then refluxed for four hours. Upon completion, the reaction is diluted with water, and extracted with DCM. The combined organics are washed with brine, dried over Na2SO4, filtered and concentrated in-vacuo (See also synthesis of
compound 3 in Example 1 and [Ref 16]). -
-
Compound 9 is dissolved in dry THF (1 eq, 0.2 M) under argon and cooled to 0° C. MeMgBr (2.2 eq, 3.0 M in Et2O) is added dropwise and the reaction is allowed to warm to room temperature. After one hour, a solution of hydrocinnamoyl chloride in DCM (2.2 eq, 0.2 M) is added dropwise, and the mixture is stirred overnight. The reaction is then quenched with saturated aqueous sodium bicarbonate, and extracted with DCM. The combined organics are dried over MgSO4, filtered and concentrated in-vacuo. The crude is flashed on silica gel eluting with 10% EtOAc:Hexane to yield the product as a clear oil. See also synthesis of compound 4 in Example 1. -
- Compound 10 (1 eq, 0.1 M) and iodomethane (3 eq) are dissolved in dry DCM and stirred at reflux overnight. The mixture is then cooled to room temperature, concentrated in-vacuo, and used directly in the next step (see also [Ref 17]).
-
- Compound 11 (1 eq, 0.2 M) and malondialdehyde bis(phenylimine).HCl (1.1 eq) are dissolved in acetic anhydride and heated to 100° C. for 30 minutes. The solution is cooled to room temperature, then a solution of 23 (1 eq, 0.2 M) in pyridine is added. The reaction is stirred overnight, then concentrated in-vacuo. The residue is purified by silica gel chromatography (see also [Ref 18]).
-
- Compound 12 (1 eq, 0.1 M) is dissolved in 1:1 THF.MeOH. At 0° C., an aqueous solution of LiOH (3 eq, 1.0 M) is added dropwise and the reaction is warmed to room temperature. After 2.5 hours, the reaction is quenched with aqueous citric acid, and extracted with DCM. The combined organics are dried over MgSO4, filtered and concentrated in-vacuo. The product is purified by silica gel chromatography. See also synthesis of
compound 1 in Example 1. - A skilled person will realize that additional functional groups can be placed on the indole rings of the cyanine by choosing the appropriate aniline derivative similar to
compound 6 above. Such different functional groups can be selected, for example, to modulate the wavelength of light absorbed by the light absorbing molecule (see e.g. [Ref 1] and [Ref 19]), to attach groups for increasing water solubility (see e.g., Example 2), or to attach heavy atoms for increasing excited state lifetimes (see e.g., Example 4). A skilled person will also realize that different alkyl iodides can be selected as in the synthesis ofcompound 11 above to place different alkyl substituents on the indole nitrogens in the final cyanine, for example, to modulate the wavelength of light absorbed by the light absorbing molecule (see e.g. [Ref 1] and [Ref 19]). - Described below is the synthesis of
photoacids FIG. 5 . -
- Compound 15 (1 eq, 1.0 M) is dissolved in 3:2 AcoH—H2O and cooled to 0° C. Concentrated HNO3 (1.1 eq) is added and the solution is heated to 65° C. for 10 minutes. After cooling to room temperature, the mixture is allowed to precipitate at 0° C. overnight. The crystalline product is collected on a sintered glass funnel and washed with ice-cold water. The solid is then dissolved in an ice-cold solution of KOH (1.1 eq, 0.5 M in 1:4 H2O—MeOH) and allowed to warm to 50° C. for 15 minutes. Cooling to 0° C. then affords a crystalline product that is filtered, washed with ice water, and dried in-vacuo.
-
- Compound 16 (1 eq) is dissolved in acetic acid (0.3 M) and added to a solution of NaNO2 (1.1 eq, 2.0 M) in concentrated H2SO4, keeping the temperature between 15-20° C. with an ice-bath. The resulting solution is added over 5 minutes to a solution of CuBr (1.1 eq, 0.05 M in 1:1 HBr—H2O) heated at 80° C. After addition, the reaction mixture is allowed to cool to room temperature and extracted with DCM. The combined organics are dried over MgSO4, filtered, and concentrated in-vacuo.
-
- Compound 17 (1 eq, 0.1 M), iron powder (3 eq), and conc. HCl (5 eq) are dissolved in EtOH and heated to reflux. After stirring 5 hours, the mixture is cooled to room temperature, made basic by addition of Na2CO3, and extracted with Et2O. The combined organics are washed with water, dried over MgSO4, filtered, passed through a plug of silica gel, and concentrated in-vacuo.
-
- A suspension of 18 (1 eq, 0.2 M) in 1:1 conc. HCl—H2O is cooled to −10° C. under Ar. A chilled solution of NaNO2 (1.1 eq, 2.0 M) in H2O is slowly added, keeping the temperature below 0° C. The solution is stirred at the temperature for 30 minutes, then a chilled solution of 5 nCl2 (3 eq, 2.0 M) in conc. HCl is added slowly. After addition, the mixture is diluted in H2O, and extracted Et2O. The remaining organic is made basic with NaOH, then extracted with Et2O. The combined organics are dried over MgSO4, filtered, and concentrated in-vacuo. The residue is taken up in AcOH, and 3-methyl-2-butanone (2.2 eq) is added. The mixture is refluxed overnight, then concentrated in-vacuo. The crude is flashed on silica gel eluting with 25% EtOAc, Hexane to obtain the product as a reddish oil.
-
- Compound 19 (1 eq, 0.1 M) is dissolved in dry DCM under Ar and cooled to 0° C. BBr3 (1.1 eq) is added dropwise, and reaction stirred at the temperature for 5 hours. The reaction is then diluted in H2O, extracted DCM, dried over MgSO4, and concentrated in-vacuo. The crude is flashed on 25% EtOAc:Hex to yield the product as a colorless oil.
-
-
Compound 20 is dissolved in iodomethane and refluxed overnight. After cooling to room temperature, the excess iodomethane is removed in-vacuo. The resulting residue is used without further purification. -
- Compound 21 (1 eq, 0.2 M) and malondialdehyde bis(phenylimine.HCl (1.1 eq) are dissolved in acetic anhydride and heated to 100° C. for 30 minutes. The solution is cooled to room temperature, then a solution of 23 (1 eq, 0.2 M) in pyridine is added. The reaction is stirred overnight, then concentrated in-vacuo. The residue is purified by silica gel chromatography to afford
compound 14 with the phenoxy group as an acetate ester. The acetate ester of 14 (1 eq, 0.1 M) is dissolved in 1:1 THF—MeOH. At 0° C., an aqueous solution of LiOH (3 eq, 1.0 M) is added dropwise and the reaction is warmed to room temperature. After 2.5 hours, the reaction is quenched with aqueous citric acid, and extracted with DCM. The combined organics are dried over MgSO4, filtered and concentrated in-vacuo. The product is purified by silica gel chromatography to affordcompound 14.Compound 13 is made in the same manner except usingindolium 24 instead of 23. -
Compound 1a (see Example 1) was decaged using the following procedure. In a quartz cuvette, 1a (0.001 M) is dissolved in spectroscopic-grade acetonitrile and irradiated at 300 nm using a 1-kW xenon arc lamp at room temperature for 15 minutes. Aliquots are removed and analyzed by analytical LC-MS utilizing a gradient elution of 10-100% acetonitrile-water over 10 minutes. The data shown represents t=0 minutes in the lower LC-MS trace, t=15 minutes in the upper LC-MS trace. - The linker with X1 in Formulas (I) and (II) being C can be synthesized according to the synthesis scheme of
FIG. 7 (see, e.g., [Ref 20]). A skilled person will realize that the reactions below are not limited and can be applied to molecules similar tocompound 27. -
- 3-hydroxy-2-naphthaldehyde (27; 1 eq, 0.1 M) is dissolved in dry DCM under Ar and cooled to 0° C. A solution of AlCl3 (1 eq, 1.0 M) in dry DCM is added, and the mixture is warmed to room temperature. Upon completion, the reaction is quenched with water, extracted with DCM, dried MgSO4, filtered and concentrated.
- A skilled person will realize that molecules similar to compound 27 can be used. By way of example, in some molecules, the aldehyde may be a precursor such as an alcohol or ester which may be oxidized or reduced, respectively, to afford an aldehyde.
-
- The aldehyde (1 eq, 0.1 M) and (carbethoxymethylene)triphenylphosphorane (1.1 eq) are dissolved in dry xylene under Ar and refluxed 13 hours. The solution is diluted in water, and extracted EtOAc, dried MgSO4, filtered and concentrated in-vacuo.
-
- Compound 29 (1 eq, 0.1 M) and Raney Nickel (20%) are stirred in aqueous NaOH (1 M) at 90° C. for 1 hour. After cooling to r.t., the reaction is quenched with 1M HCl, and extracted with DCM. The combined organics are dried over MgSO4, filtered and concentrated in-vacuo. The residue is taken up in dry benzene and refluxed with PTSA (1 eq) for 1 hour. The mixture is cooled, extracted with EtOAc, dried with MgSO4, filtered and concentrated in-vacuo.
-
- Compound 30 (1 eq, 0.2 M) is dissolved in dry THF under Ar and cooled to 0° C. A solution of MeMgBr (2.2 eq, 3.0 M in Et2O) is added dropwise, and the reaction is allowed to warm to room temperature over 1 hour. To the solution is then added hydrocinnamoyl chloride (2.2 eq, 0.2 M) as a solution in DCM. The mixture is stirred at room temperature overnight, then quenched with water. The mixture is extracted with DCM, and the combined organics are dried with MgSO4, filtered and concentrated in-vacuo. The resulting residue is taken up in 1:1 THF-MeOH, and cooled to 0° C. Aqueous LiOH (3 eq, 1 M) is added dropwise, and the reaction is warmed to room temperature. After stirring 1 hour, the reaction is quenched with aq. citric acid, extracted DCM, dried MgSO4, filtered, and concentrated in-vacuo. The residue is purified by silica gel chromatography.
- A skilled person will realize that cyanine-based [
Ref 1, 19] photoacid compounds in addition to those above can be synthesized using general methods. These general reaction methods are shown inFIG. 8A-F . -
FIG. 8A shows a general synthetic strategy to synthesize photoacid compounds of Formula (I) using a common precursor (ortho dihydroxyarene; 32). InFIG. 8A , X′ and Y′ are linked together to form part of an arene or heteroarene.Compound 32 is then carried through the steps of Example 1 and/or Example 3 to providecompound 34, shown inFIG. 8A with an optional protecting group (PG; see [Ref 9] and [Ref 8]). -
FIG. 8B shows a general synthetic scheme for the synthesis of closed chain cyanines with a variable-length polyene and variable heteroaryl groups. InFIG. 8B , commercially available precursors are converted tocompounds 36 and 35 (which can be converted into compound 36), and compound 26 is converted into compound 37 (see, e.g. [Ref 21]). In compounds 35, 36, and 37, X is nitrogen and Y is a heteroatom such as, for example, N, O, or S. Groups Ra and Rb incompounds compound 32 and can be carried through the steps ofFIG. 8A . Similarly, when Ra and Rb are O-alkyl, they may be subjected to Deprotection conditions (see, e.g., synthesis ofcompound 8 in Example 3) to afford a dihydroxylated arene or heteroarene can be of the form ofcompound 32. -
FIG. 8C shows an exemplary application of the synthesis shown inFIG. 8B to the general synthesis of photoacid compounds with cyanine light absorbing moieties. InFIG. 8C , compound 34 fromFIG. 8A is carried through the synthetic steps ofFIG. 8B (with a deprotection step; see [Ref 9] and [Ref 8]) to afford a photoacidic compound (29) as herein described with payload moiety R3. -
FIG. 8D shows a photoactive molecule with a particular desired absorbance wavelength (compound 40) and an analogous photoactive compound as herein described (compound 41) incorporatingcompound 40 as the light absorbing moiety.Compound 40 can be synthesized using the quinolinium 44 (analogous to compound 36) using the methods ofFIG. 8B . The synthesis ofquinolinium 44 can be accomplished using the reactions ofFIG. 8E . -
FIG. 8F shows the synthesis ofphotoacid compound 41 according to the methods ofFIG. 8A ,FIG. 8B , andFIG. 8E .Compound 45, which can be synthesized in one step from a commercially available compound, is converted to dihydroxyquinoline 43 via the first reaction ofFIG. 8E .Dihydroxyquinoline 43 can then be converted to compound 47 via the reactions ofFIG. 8A .Compound 47 can then be converted toquinolinium 48 via the second reaction ofFIG. 8E .Quinolinium 48 can in turn be converted tophotoacid compound 41 via the last reaction ofFIG. 8B similar to what is done inFIG. 8C . - The examples set forth above are provided to give those of ordinary skill in the art a complete disclosure and description of how to make and use the embodiments photoacid compounds and related compositions, methods, and systems of the disclosure, and are not intended to limit the scope of what the Applicants regard as their disclosure. Modifications of the above-described modes for carrying out the disclosure can be used by persons of skill in the art, and are intended to be within the scope of the following claims.
- The entire disclosure of each document cited (including patents, patent applications, journal articles including related supplemental and/or supporting information sections, abstracts, laboratory manuals, books, or other disclosures) in the Background, Summary, Detailed Description, and Examples is hereby incorporated herein by reference. All references cited in this disclosure are incorporated by reference to the same extent as if each reference had been incorporated by reference in its entirety individually. However, if any inconsistency arises between a cited reference and the present disclosure, the present disclosure takes precedence.
- The terms and expressions which have been employed herein are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the disclosure claimed. Thus, it should be understood that although the disclosure has been specifically disclosed by preferred embodiments, exemplary embodiments and optional features, modification and variation of the concepts herein disclosed can be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this disclosure as defined by the appended claims.
- It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting. As used in this specification and the appended claims, the singular forms “a,” an and the include plural referents unless the content clearly dictates otherwise. The term “plurality” includes two or more referents unless the content clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains.
- The term “alkyl” as used herein refers to a linear, branched, or cyclic saturated hydrocarbon group typically although not necessarily containing 1 to about 15 carbon atoms, or 1 to about 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, octyl, decyl, and the like, as well as cycloalkyl groups such as cyclopentyl, cyclohexyl and the like. Generally, although again not necessarily, alkyl groups herein contain 1 to about 15 carbon atoms. The term “cycloalkyl” intends a cyclic alkyl group, typically having 4 to 8, or 5 to 7, carbon atoms. The term “substituted alkyl” refers to alkyl substituted with one or more substituent groups, and the terms “heteroatom-containing alkyl” and “heteroalkyl” refer to alkyl in which at least one carbon atom is replaced with a heteroatom. If not otherwise indicated, the terms “alkyl” and “lower alkyl” include linear, branched, cyclic, unsubstituted, substituted, and/or heteroatom-containing alkyl and lower alkyl, respectively.
- The term “hydrocarbyl” as used herein refers to any univalent radical, derived from a hydrocarbon, such as, for example, methyl or phenyl. The term “hydrocarbylene” refers to divalent groups formed by removing two hydrogen atoms from a hydrocarbon, the free valencies of which may or may not be engaged in a double bond, typically but not necessarily containing 1 to 20 carbon atoms, in particular 1 to 12 carbon atoms and more particularly 1 to 6 carbon atoms which includes but is not limited to linear cyclic, branched, saturated and unsaturated species, such as alkylene, alkenylene alkynylene and divalent aryl groups, e.g., 1,3-phenylene, —CH2CH2CH2-propane-1,3-diyl, —CH2-methylene, —CH═CH—CH═CH—. The term “hydrocarbyl” as used herein refers to univalent groups formed by removing a hydrogen atom from a hydrocarbon, typically but not necessarily containing 1 to 20 carbon atoms, in particular 1 to 12 carbon atoms and more particularly 1 to 6 carbon atoms, including but not limited to linear cyclic, branched, saturated and unsaturated species, such as univalent alkyl, alkenyl, alkynyl and aryl groups e.g. ethyl and phenyl groups.
- The term “heteroatom-containing” as in a “heteroatom-containing alky group” refers to a alkyl group in which one or more carbon atoms is replaced with an atom other than carbon, e.g., nitrogen, oxygen, sulfur, phosphorus or silicon, typically nitrogen, oxygen or sulfur. Similarly, the term “heteroalkyl” refers to an alkyl substituent that is heteroatom-containing, the term “heterocyclic” refers to a cyclic substituent that is heteroatom-containing, the terms “heteroaryl” and “heteroaromatic” respectively refer to “aryl” and “aromatic” substituents that are heteroatom-containing, and the like. It should be noted that a “heterocyclic” group or compound may or may not be aromatic, and further that “heterocycles” may be monocyclic, bicyclic, or polycyclic as described above with respect to the term “aryl.” Examples of heteroalkyl groups include alkoxyaryl, alkylsulfanyl-substituted alkyl, N-alkylated amino alkyl, and the like. Examples of heteroaryl substituents include pyrrolyl, pyrrolidinyl, pyridinyl, quinolinyl, indolyl, pyrimidinyl, imidazolyl, 1,2,4-triazolyl, tetrazolyl, and others known to a skilled person, and examples of heteroatom-containing alicyclic groups are pyrrolidino, morpholino, piperazino, piperidino, and other known to a skilled person.
- The term “alkoxy” as used herein intends an alkyl group bound through a single, terminal ether linkage; that is, an “alkoxy” group may be represented as —O-alkyl where alkyl is as defined above. A “lower alkoxy” group intends an alkoxy group containing 1 to 6 carbon atoms. Analogously, “alkenyloxy” and “lower alkenyloxy” respectively refer to an alkenyl and lower alkenyl group bound through a single, terminal ether linkage, and “alkynyloxy” and “lower alkynyloxy” respectively refer to an alkynyl and lower alkynyl group bound through a single, terminal ether linkage.
- The term “alkylamino” as used herein intends an alkyl group bound through a single terminal amine linkage; that is, an “alkylamino” may be represented as —NH-alkyl where alkyl is as defined above. A “lower alkylamino” intends a alkylamino group containing 1 to 6 carbon atoms. The term “dialkylamino” as used herein intends two identical or different bound through a common amine linkage; that is, a “dialkylamino” may be represented as —N(alkyl)2 where alkyl is as defined above. A “lower dialkylamino” intends a alkylamino wherein each alkyl group contains 1 to 6 carbon atoms. Analogously, “alkenylamino”, “lower alkenylamino”, “alkynylamino”, and “lower alkynylamino” respectively refer to an alkenyl, lower alkenyl, alkynyl and lower alkynyl bound through a single terminal amine linkage; and “dialkenylamino”, “lower dialkenylamino”, “dialkynylamino”, “lower dialkynylamino” respectively refer to two identical alkenyl, lower alkenyl, alkynyl and lower alkynyl bound through a common amine linkage. Similarly, “alkenylalkynylamino”, “alkenylalkylamino”, and “alkynylalkylamino” respectively refer to alkenyl and alkynyl, alkenyl and alkyl, and alkynyl and alkyl groups bound through a common amine linkage.
- The term “aryl” as used herein, and unless otherwise specified, refers to an aromatic substituent containing a single aromatic ring or multiple aromatic rings that are fused together, directly linked, or indirectly linked (such that the different aromatic rings are bound to a common group such as a methylene or ethylene moiety). Aryl groups can contain 5 to 24 carbon atoms, or aryl groups contain 5 to 14 carbon atoms. Exemplary aryl groups contain one aromatic ring or two fused or linked aromatic rings, e.g., phenyl, naphthyl, biphenyl, diphenylether, diphenylamine, benzophenone, and the like. “Substituted aryl” refers to an aryl moiety substituted with one or more substituent groups, and the terms “heteroatom-containing aryl” and “heteroaryl” refer to aryl substituents in which at least one carbon atom is replaced with a heteroatom, as will be described in further detail infra.
- The term “arene”, as used herein, refers to an aromatic ring or multiple aromatic rings that are fused together. Exemplary arenes include, for example, benzene, naphthalene, anthracene, and the like. The term “heteroarene”, as used herein, refers to an arene in which one or more of the carbon atoms has been replaced by a heteroatom (e.g. O, N, or S). Exemplary heteroarenes include, for example, indole, benzimidazole, thiophene, benzthiazole, and the like. The terms “substituted arene” and “substituted heteroarene”, as used herein, refer to arene and heteroarene molecules in which one or more of the carbons and/or heteroatoms are substituted with substituent groups.
- The terms “cyclic”, “cyclo-”, and “ring” refer to alicyclic or aromatic groups that may or may not be substituted and/or heteroatom containing, and that may be monocyclic, bicyclic, or polycyclic. The term “alicyclic” is used in the conventional sense to refer to an aliphatic cyclic moiety, as opposed to an aromatic cyclic moiety, and may be monocyclic, bicyclic or polycyclic.
- The terms “halo”, “halogen”, and “halide” are used in the conventional sense to refer to a chloro, bromo, fluoro or iodo substituent or ligand.
- The term “substituted” as in “substituted alkyl,” “substituted aryl,” and the like, is meant that in the, alkyl, aryl, or other moiety, at least one hydrogen atom bound to a carbon (or other) atom is replaced with one or more non-hydrogen substituents.
- Examples of such substituents include, without limitation: functional groups such as halo, hydroxyl, sulfhydryl, C1-C24 alkoxy, C2-C24 alkenyloxy, C2-C24 alkynyloxy, C5-C24 aryloxy, C6-C24 aralkyloxy, C6-C24 alkaryloxy, acyl (including C2-C24 alkylcarbonyl (—CO-alkyl) and C6-C24 arylcarbonyl (—CO-aryl)), acyloxy (—O-acyl, including C2-C24 alkylcarbonyloxy (—O—CO-alkyl) and C6-C24 arylcarbonyloxy (—O—CO-aryl)), C2-C24 alkoxycarbonyl (—(CO)—O-alkyl), C6-C24 aryloxycarbonyl (—(CO)—O-aryl), halocarbonyl (—CO)—X where X is halo), C2-C24 alkylcarbonato (—O—(CO)-β-alkyl), C6-C24 arylcarbonato (—O—(CO)—O-aryl), carboxy (—COOH), carboxylato (COO−), carbamoyl (—(CO)—NH2), mono-(C1-C24 alkyl)-substituted carbamoyl (—(CO)—NH(C1-C24 alkyl)), di-(C1-C24 alkyl)-substituted carbamoyl (—(CO)—N(C1-C24 alkyl)2), mono-(C5-C24 aryl)-substituted carbamoyl (—(CO)—NH-aryl), di-(C5-C24 aryl)-substituted carbamoyl (—(CO)—N(C5-C24 aryl)2), di-N—(C1-C24 alkyl),N—(C5-C24 aryl)-substituted carbamoyl, thiocarbamoyl (—(C5-NH2), mono-(C1-C24 alkyl)-substituted thiocarbamoyl (—(CO)—NH(C1-C24 alkyl)), di-(C1-C24 alkyl)-substituted thiocarbamoyl (—(CO)—N(C1-C24 alkyl)2), mono-(C5-C24 aryl)-substituted thiocarbamoyl (—(CO)—NH-aryl), di-(C5-C24 aryl)-substituted thiocarbamoyl (—(CO)—N(C5-C24 aryl)2), di-N—(C1-C24 alkyl),N—(C5-C24 aryl)-substituted thiocarbamoyl, carbamido (—NH—(CO)—NH2), cyano(—C≡N), cyanato (—O—C≡H), thiocyanato (—S—C≡N), formyl (—(CO)—H), thioformyl ((CS)—H), amino (—NH2), mono-(C1-C24 alkyl)-substituted amino, di-(C1-C24 alkyl)-substituted amino, mono-(C5-C24 aryl)-substituted amino, di-(C5-C24 aryl)-substituted amino, C2-C24 alkylamido (—NH—(CO)-alkyl), C6-C24 arylamido (—NH—(CO)-aryl), imino (—CR═NH where R=hydrogen, C1-C24 alkyl, C5-C24 aryl, C6-C24 alkaryl, C6-C24 aralkyl, and others known to a skilled person), C2-C20 alkylimino (CR═N(alkyl), where R=hydrogen, C1-C24 alkyl, C5-C24 aryl, C6-C24 alkaryl, C6-C24 aralkyl, and others known to a skilled person), arylimino (—CR═N(aryl), where R=hydrogen, C1-C20 alkyl, C5-C24 aryl, C6-C24 alkaryl, C6-C24 aralkyl, and others known to a skilled person), nitro (—NO2), nitroso (—NO), sulfo (—SO2-OH), sulfonato (—SO2-O−), C1-C24 alkylsulfanyl (—S-alkyl; also termed “alkylthio”), C5-C24 arylsulfanyl (—S-aryl; also termed “arylthio”), C1-C24 alkylsulfinyl (—(SO)-alkyl), C5-C24 arylsulfinyl (—(SO)-aryl), C1-C24 alkylsulfonyl (—SO2-alkyl), C5-C24 arylsulfonyl (—SO2-aryl), boryl (—BH2), borono (—B(OH)2), boronato (—B(OR)2 where R is alkyl or other hydrocarbyl), phosphono (—P(O)(OH)2), phosphonato (—P(O)(O−)2), phosphinato (—P(O)(O−), phospho (—PO2), phosphino (—PH2), silyl (—SiR3 wherein R is hydrogen or hydrocarbyl), and silyloxy (—O-silyl); and the hydrocarbyl moieties C1-C24 alkyl (e.g. C1-C12 alkyl and C1-C6 alkyl), C2-C24 alkenyl (e.g. C2-C12 alkenyl and C2-C6 alkenyl), C2-C24 alkynyl (e.g. C2-C12 alkynyl and C2-C6 alkynyl), C5-C24 aryl (e.g. C5-C14 aryl), C6-C24 alkaryl (e.g. C6-C16 alkaryl), and C6-C24 aralkyl (e.g. C6-C16 aralkyl).
- The term “acyl” refers to substituents having the formula —(CO)-alkyl, —(CO)-aryl, or —(CO)-aralkyl, and the term “acyloxy” refers to substituents having the formula —O(CO)-alkyl, —O(CO)-aryl, or —O(CO)-aralkyl, wherein “alkyl,” “aryl, and “aralkyl” are as defined above.
- The term “alkaryl” refers to an aryl group with an alkyl substituent, and the term “aralkyl” refers to an alkyl group with an aryl substituent, wherein “aryl” and “alkyl” are as defined above. In some embodiments, alkaryl and aralkyl groups contain 6 to 24 carbon atoms, and particularly alkaryl and aralkyl groups contain 6 to 16 carbon atoms. Alkaryl groups include, for example, p-methylphenyl, 2,4-dimethylphenyl, p-cyclohexylphenyl, 2,7-dimethylnaphthyl, 7-cyclooctylnaphthyl, 3-ethyl-cyclopenta-1,4-diene, and the like. Examples of aralkyl groups include, without limitation, benzyl, 2-phenyl-ethyl, 3-phenyl-propyl, 4-phenyl-butyl, 5-phenyl-pentyl, 4-phenylcyclohexyl, 4-benzylcyclohexyl, 4-phenylcyclohexylmethyl, 4-benzylcyclohexylmethyl, and the like. The terms “alkaryloxy” and “aralkyloxy” refer to substituents of the formula —OR wherein R is alkaryl or aralkyl, respectively, as just defined.
- When a Markush group or other grouping is used herein, all individual members of the group and all combinations and possible subcombinations of the group are intended to be individually included in the disclosure. Every combination of components or materials described or exemplified herein can be used to practice the disclosure, unless otherwise stated. One of ordinary skill in the art will appreciate that methods, device elements, and materials other than those specifically exemplified can be employed in the practice of the disclosure without resort to undue experimentation. All art-known functional equivalents, of any such methods, device elements, and materials are intended to be included in this disclosure.
- Whenever a range is given in the specification, for example, a temperature range, a frequency range, a time range, or a composition range, all intermediate ranges and all subranges, as well as, all individual values included in the ranges given are intended to be included in the disclosure. Any one or more individual members of a range or group disclosed herein can be excluded from a claim of this disclosure. The disclosure illustratively described herein suitably can be practiced in the absence of any element or elements, limitation or limitations, which is not specifically disclosed herein.
- “Optional” or “optionally” means that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not according to the guidance provided in the present disclosure. For example, the phrase “optionally substituted” means that a non-hydrogen substituent may or may not be present on a given atom, and, thus, the description includes structures wherein a non-hydrogen substituent is present and structures wherein a non-hydrogen substituent is not present. It will be appreciated that the phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.” Unless otherwise indicated, an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position. Combinations of substituents envisioned can be identified in view of the desired features of the compound in view of the present disclosure, and in view of the features that result in the formation of stable or chemically feasible compounds. The term “stable”, as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
- A number of embodiments of the disclosure have been described. The specific embodiments provided herein are examples of useful embodiments of the disclosure and it will be apparent to one skilled in the art that the disclosure can be carried out using a large number of variations of the devices, device components, methods steps set forth in the present description. As will be obvious to one of skill in the art, methods and devices useful for the present methods can include a large number of optional composition and processing elements and steps.
- In particular, it will be understood that various modifications may be made without departing from the spirit and scope of the present disclosure. Accordingly, other embodiments are within the scope of the following claims.
-
- 1. Fabian, J., et al., “Near-infrared absorbing dyes.” Chem Rev 1992 92(6): 1197-1226.
- 2. Pines, D. P., Ehund, “Solvent Assisted Photoacidity”, in Handbook of Hydrogen Transfer, R. L. Schowen, Editor. 2006, Wiley-VCH: Weinheim, Germany. p. 377-415.
- 3. Tolbert, L. M., et al., “Excited-State Proton Transfer: From Constrained Systems to “Super” Photoacids to Superfast Proton Transfer.” Accounts of Chemical Research 2002 35(1): 19-27.
- 4. Agmon, N., et al., “Electronic determinants of photoacidity in cyanonaphthols.” J Am Chem Soc 2002 124(6): 1089-1096.
- 5. Anslyn, E. V., et al., “Modern physical organic chemistry”. 2006: University Science Books.
- 6. Turro, N. J., “Modern molecular photochemistry”. 2010, Sausalito, Calif.: University Science Books.
- 7. Johnson, I. D., et al., “The Molecular Probes Handbook: A Guide to Fluorescent Probes and Labeling Technologies”. 2010: Life Technologies.
- 8. Kocienski, P., “Protecting Groups (softcover)”. 2005: Thieme.
- 9. Greene, T., et al., “Protecting groups in organic synthesis”. Wiley, New York. 1999. 297-348.
- 10. “Sandmeyer Reaction.” Organic Syntheses [Accessed Dec. 5, 2012]; Available from: http://www.organic-chemistry.org/namedreactions/sandmeyer-reaction.shtm.
- 11. Lait, S. M., et al., “Synthesis of a 1,3-spiro-amino-alcohol-derived chiral auxiliary and its application to Diels-Alder reactions.” Tetrahedron: Asymmetry 2003 14(6): 749-756.
- 12. “Reductive Amination.” Organic Syntheses [Accessed Dec. 4, 2012];
Available from: http://www.organic-chemistry.org/synthesis/C1N/amines/reductiveamination.shtm. - 13. Joullié, M. M., et al., “Evolution of amide bond formation” Arkivoc 2010 8: 189-250.
- 14. Niu, S. “Advanced Water Soluble BODIPY Dyes: Synthesis and Application.” Ph.D. Thesis, University of Strasbourg, July 2011
- 15. Niu, S. L., et al., “Water-soluble BODIPY derivatives.” Org Lett 2009 11(10): 2049-2052.
- 16. Gandolfi, C. A., et al., “N-acyl-2-substituted-1,3-thiazolidines, a new class of non-narcotic antitussive agents: studies leading to the discovery of ethyl 2-[(2-methoxyphenoxy)methyl]-beta-oxothiazolidine-3-propanoate.” J Med Chem 1995 38(3): 508-525.
- 17. Oushiki, D., et al., “Near-infrared fluorescence probes for enzymes based on binding affinity modulation of squarylium dye scaffold.” Anal Chem 2012 84(10): 4404-4410.
- 18. Gerowska, M., et al., “Efficient reverse click labeling of azide oligonucleotides with multiple alkynyl Cy-Dyes applied to the synthesis of HyBeacon probes for genetic analysis.” Tetrahedron 2012 68(3): 857-864.
- 19. Mishra, A., et al., “Cyanines during the 1990s: A Review.” Chem Rev 2000 100(6): 1973-2012.
- 20. Ranade, A. A., et al., “A facile synthesis of dihydronaphthopyrans.” Journal of Chemical Research 2003 2003(8): 461-462.
- 21. Mason, S. J., et al., “Solid-phase methods for the synthesis of cyanine dyes.” J Org Chem 2005 70(8): 2939-2949.
Claims (31)
1. A photoacid compound comprising
a light absorbing moiety attaching an payload moiety through a linker moiety
wherein
the linker moiety is an organic moiety comprising a geminal dialkyl moiety linked to an ester group having a carbonyl oxygen, the carbonyl group of the ester attaching the payload moiety;
the light absorbing moiety is an organic moiety attaching the linker moiety in ortho position to a hydroxyl group; and
the linker is configured to present the carbonyl oxygen for reaction with the hydroxyl group.
2. The photoacid compound of claim 1 wherein the light-absorbing moiety is a substituted or unsubstituted polycyclic aromatic hydrocarbon, a substituted or unsubstituted closed chain cyanine, or a substituted or unsubstituted hemicyanine.
3. The photoacid compound of claim 1 , wherein the light absorbing moiety is able to absorb light at a wavelength of from about 900 nm to about 1100 nm.
4. The photoacid compound of claim 1 , wherein the geminal dialkyl moiety can be joined together to form a cyclic moiety.
5. The photoacid compound of claim 1 , wherein the linker moiety is a monoalkoxy or a dialkoxy moiety in which an oxy group forms part of the ester group having the carbonyl oxygen.
6. The photoacid compound of claim 1 , wherein the payload moiety is a substituted or unsubstituted alkyl, aryl, heteroaryl, alkoxy, alkylamino, or dialkylamino moiety.
7. A photoacid compound according to formula (I):
wherein:
R4 is a light-absorbing moiety presenting a hydroxyl group for interaction with the carbonyl oxygen of the R3(CO)O group, wherein the light-absorbing moiety is a substituted or unsubstituted polycyclic aromatic hydrocarbon, a substituted or unsubstituted closed chain cyanine, or a substituted or unsubstituted hemicyanine, and wherein the hydroxyl group is covalently bonded to the polycyclic aromatic hydrocarbon, the closed chain cyanine, or the hemicyanine, and the hydroxyl group is in a position ortho to X1;
R3 is a payload moiety, wherein the payload moiety is a substituted or unsubstituted alkyl, aryl, heteroaryl, alkoxy, alkylamino, or dialkylamino moiety;
X1 is independently selected from the group consisting of C and O;
m is between 0 and 3; and
R1 and R2 are independently C1-C6 alkyl groups, cycloalkyl, or substituted or unsubstituted hydrocarbylene groups wherein when R1 and R2 are substituted or unsubstituted hydrocarbylene groups, R1 and R2 are linked together to form a cyclic moiety.
8. The photoacidic compound according to claim 7 , wherein X1 is O and R1 and R2 are methyl, ethyl, or are linked together to form a cyclopentyl or cyclohexyl moiety.
9. The photoacidic compound according to claim 7 , wherein X1 is C and R1 and R2 are methyl, ethyl, or are linked together to form a cyclopentyl or cyclohexyl moiety.
11. The photoacidic compound according to claim 10 , wherein n is O.
13. The photoacid of claim 12 , wherein m is 2 and n is 0.
15. The photoacid compound of claim 14 , wherein p is 2.
17. The photoacid compound of claim 16 , wherein q is 2.
19. The photoacid compound of claim 18 , wherein r is 2.
20. The photoacid of claim 7 , wherein R3 has the structure of formula (VII):
21. The photoacid of claim 7 , wherein R3 has the structure of formula (VIII):
wherein:
n is between 1 and 5;
Rα, Rβ, and Rγ are independently H, or substituted or unsubstituted alkyl, alkylamino, alkoxy, aryl, arylamino, aryloxy, heteroaryl, hetroarylamino, and heteroaryloxy; and
wherein when n is greater than 1, the Rα and Rβ of each C(Rα)(Rβ) unit are independent of the Rα and Rβ of the other units.
22. The photoacid of claim 7 , wherein R3 has the structure of formula (IX):
wherein:
p is between 1 and 5;
Rα, Rβ, and Rγ are independently H, or substituted or unsubstituted alkyl, alkylamino, alkoxy, aryl, arylamino, aryloxy, heteroaryl, hetroarylamino, and heteroaryloxy, wherein Rδ is H, substituted or unsubstituted alkyl, acyl, aryl; and
wherein when p is greater than 1, the Rα and Rβ of each C(Rα)(Rβ) unit are independent of the Rα and Rβ of the other units.
23. The photoacid of claim 7 , wherein R3 has the structure of formula (X):
wherein
m is between 1 and 5;
Rα, Rβ, and Rγ are independently H, or substituted or unsubstituted alkyl, alkylamino, alkoxy, aryl, arylamino, aryloxy, heteroaryl, hetroarylamino, and heteroaryloxy; and
wherein when m is greater than 1, the Rα and Rβ of each C(Rα)(Rβ) unit are independent of the Rα and Rβ of the other units.
24. The photoacid of claim 7 , wherein R3 has the structure of formula (XI):
wherein
q is between 0 and 4;
Rα is H, or substituted or unsubstituted alkyl, alkylamino, alkoxy, aryl, arylamino, aryloxy, heteroaryl, hetroarylamino, and heteroaryloxy;
ε is a substituted or unsubstituted hydrocarbylene, X is C or N; and
wherein when q is greater than 1, each Rα is independent of the other Rα substituents.
26. A method to deliver a compound, comprising
providing a caged compound, the caged compound being caged as a payload moiety within the photoacid compound of claim 1 , the photoacid compound being in a ground state in which the hydrogen substituted heteroatom presented on the light absorbing moiety of the photoacid compound has a ground state pKa; and
uncaging the caged compound by irradiating the photoacid compound with light at a wavelength suitable to promote the photoacid compound to an excited state wherein the hydrogen substituted heteroatom presented on the light absorbing moiety of the photoacid compound has an excited state pKa lower than the ground state pKa.
27. The method according to claim 26 , wherein the wavelength of the light is greater than 750 nm.
28. The method according to claim 26 , wherein irradiating the photoacid compound is performed with light at a wavelength between about 750 and about 1400 nm.
29. The method according to claim 26 , wherein irradiating the photoacid compound is performed with light at a wavelength between about between about 900 and about 1100 nm.
30. The method according to claim 26 , wherein irradiating the photoacid compound is performed with light at a wavelength less than about 750 nm.
31. A system to deliver a compound, the system comprising at least two of:
one photoacid compound of claim 1 ; and
a light source suitable to irradiate light at a suitable wavelength, for simultaneous, combined or sequential use in a method to deliver a compound, comprising
providing a caged compound, the caged compound being caged as a payload moiety within a photoacid compound of claim 1 , the photoacid compound being in a ground state in which the hydrogen substituted heteroatom presented on the light absorbing moiety of the photoacid compound has a ground state pKa; and
uncaging the caged compound by irradiating the photoacid compound with light at a wavelength suitable to promote the photoacid compound to an excited state wherein the hydrogen substituted heteroatom presented on the light absorbing moiety of the photoacid compound has an excited state pKa lower than the ground state pKa.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/362,887 US20140311890A1 (en) | 2011-12-07 | 2012-12-07 | Photoacid compounds, and related compositions, methods and systems |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161568046P | 2011-12-07 | 2011-12-07 | |
PCT/US2012/068629 WO2013086460A1 (en) | 2011-12-07 | 2012-12-07 | Photoacid compounds, and related compositions, methods and systems |
US14/362,887 US20140311890A1 (en) | 2011-12-07 | 2012-12-07 | Photoacid compounds, and related compositions, methods and systems |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140311890A1 true US20140311890A1 (en) | 2014-10-23 |
Family
ID=48574960
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/362,887 Abandoned US20140311890A1 (en) | 2011-12-07 | 2012-12-07 | Photoacid compounds, and related compositions, methods and systems |
US14/362,888 Active US9636656B2 (en) | 2011-12-07 | 2012-12-07 | Caged compound delivery and related compositions, methods and systems |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/362,888 Active US9636656B2 (en) | 2011-12-07 | 2012-12-07 | Caged compound delivery and related compositions, methods and systems |
Country Status (2)
Country | Link |
---|---|
US (2) | US20140311890A1 (en) |
WO (2) | WO2013086457A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180060103A (en) * | 2016-11-28 | 2018-06-07 | 이화여자대학교 산학협력단 | Chemosensor for thiol-containing amino acid and detection method of sepsis using the same |
WO2021150621A1 (en) * | 2020-01-21 | 2021-07-29 | The Regents Of The University Of California | Spacer-mediated control of uncaging photocaged molecules |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140311890A1 (en) * | 2011-12-07 | 2014-10-23 | California Institute Of Technology | Photoacid compounds, and related compositions, methods and systems |
US9879328B2 (en) | 2014-11-21 | 2018-01-30 | GeneWeave Biosciences, Inc. | Mechanisms of antimicrobial susceptibility |
US10874876B2 (en) * | 2018-01-26 | 2020-12-29 | International Business Machines Corporation | Multiple light sources integrated in a neural probe for multi-wavelength activation |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070072115A1 (en) * | 2005-09-21 | 2007-03-29 | Shin-Etsu Chemical Co., Ltd. | Positive resist compositions and patterning process |
US20110065040A1 (en) * | 2009-09-16 | 2011-03-17 | Sumitomo Chemical Company, Limited | Photoresist composition |
US20140308208A1 (en) * | 2011-12-07 | 2014-10-16 | California Institute Of Technology | Caged compound delivery and related compositions, methods and systems |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5998580A (en) * | 1995-10-13 | 1999-12-07 | Fay; Frederick F. | Photosensitive caged macromolecules |
US6274086B1 (en) | 1996-12-16 | 2001-08-14 | The Trustees Of The University Of Pennsylvania | Apparatus for non-invasive imaging oxygen distribution in multi-dimensions |
ATE313353T1 (en) * | 1997-08-25 | 2006-01-15 | Advanced Photodynamic Technolo | DEVICE FOR TOPICAL PHOTODYNAMIC THERAPY |
US7332477B2 (en) * | 2003-07-10 | 2008-02-19 | Nitto Denko Corporation | Photocleavable DNA transfer agent |
WO2008049036A2 (en) * | 2006-10-17 | 2008-04-24 | Zymera, Inc. | Enzyme detection system with caged substrates |
JP5416889B2 (en) | 2007-06-08 | 2014-02-12 | 三菱レイヨン株式会社 | Resist polymer, resist composition, and method for producing substrate on which pattern is formed |
WO2010039886A1 (en) | 2008-09-30 | 2010-04-08 | Clarimedix | Methods and devices for visible light modulation of mitochondrial function in hypoxia and disease |
JP6061678B2 (en) * | 2009-11-04 | 2017-01-18 | アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティーArizona Board of Regents on behalf of Arizona State University | Brain control interface device |
-
2012
- 2012-12-07 US US14/362,887 patent/US20140311890A1/en not_active Abandoned
- 2012-12-07 WO PCT/US2012/068626 patent/WO2013086457A1/en active Application Filing
- 2012-12-07 US US14/362,888 patent/US9636656B2/en active Active
- 2012-12-07 WO PCT/US2012/068629 patent/WO2013086460A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070072115A1 (en) * | 2005-09-21 | 2007-03-29 | Shin-Etsu Chemical Co., Ltd. | Positive resist compositions and patterning process |
US20110065040A1 (en) * | 2009-09-16 | 2011-03-17 | Sumitomo Chemical Company, Limited | Photoresist composition |
US20140308208A1 (en) * | 2011-12-07 | 2014-10-16 | California Institute Of Technology | Caged compound delivery and related compositions, methods and systems |
Non-Patent Citations (1)
Title |
---|
Klan ("Photoremovable Protecting Groups in Chemistry and Biology: Reaction Mechanisms and Efficacy", Chemical Reviews, 2013, 113, p. 119-191) * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180060103A (en) * | 2016-11-28 | 2018-06-07 | 이화여자대학교 산학협력단 | Chemosensor for thiol-containing amino acid and detection method of sepsis using the same |
KR101879061B1 (en) * | 2016-11-28 | 2018-07-16 | 이화여자대학교 산학협력단 | Chemosensor for thiol-containing amino acid and detection method of sepsis using the same |
WO2021150621A1 (en) * | 2020-01-21 | 2021-07-29 | The Regents Of The University Of California | Spacer-mediated control of uncaging photocaged molecules |
Also Published As
Publication number | Publication date |
---|---|
WO2013086457A1 (en) | 2013-06-13 |
US9636656B2 (en) | 2017-05-02 |
US20140308208A1 (en) | 2014-10-16 |
WO2013086460A1 (en) | 2013-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8344158B2 (en) | Fluorescent polymethine cyanine dyes | |
Wang et al. | Carboxyl BODIPY dyes from bicarboxylic anhydrides: one-pot preparation, spectral properties, photostability, and biolabeling | |
US20140311890A1 (en) | Photoacid compounds, and related compositions, methods and systems | |
Isik et al. | Chromogenic and fluorogenic sensing of biological thiols in aqueous solutions using BODIPY-based reagents | |
Guy et al. | Convergent preparation and photophysical characterization of dimaleimide dansyl fluorogens: elucidation of the maleimide fluorescence quenching mechanism | |
JP5177427B2 (en) | Fluorescent compound and labeling agent comprising the same | |
Knorr et al. | New Red‐Emitting Tetrazine‐Phenoxazine Fluorogenic Labels for Live‐Cell Intracellular Bioorthogonal Labeling Schemes | |
Khan et al. | Synthesis and photophysical investigation of (BTHN) Schiff base as off-on Cd2+ fluorescent chemosensor and its live cell imaging | |
US20200248069A1 (en) | Fluorescent probe, preparation method therefor and use thereof | |
Lai et al. | Special reactive oxygen species generation by a highly photostable BODIPY-based photosensitizer for selective photodynamic therapy | |
CN111303139B (en) | Compound with aggregation-induced emission performance and preparation method and application thereof | |
CN107375929B (en) | Photosensitizer and derivatives and application thereof | |
Markova et al. | Comparison of a series of hydrophilic squaraine and cyanine dyes for use as biological labels | |
CN102352118B (en) | Near infrared fluorescent dye, preparation and application thereof | |
Yan et al. | NIR organic dyes based on phenazine-cyanine for photoacoustic imaging-guided photothermal therapy | |
Jouanno et al. | Kondrat’eva ligation: Diels–Alder-based irreversible reaction for bioconjugation | |
US9791463B2 (en) | Methods for the selective detection of alkyne-presenting molecules and related compositions and systems | |
Mtiraoui et al. | 1, 5-Benzodiazepin-2-ones: Investigation of a family of photoluminescent materials | |
Mohammad et al. | Structurally modified indocyanine green dyes. Modification of the polyene linker | |
Buschbeck et al. | Orthogonally protected diaminoterephthalate scaffolds: installation of two functional units at the chromophore | |
Ma et al. | Enhanced singlet oxygen generation of a soft salt through efficient energy transfer between two ionic metal complexes | |
Ni et al. | Convenient construction of fluorescent markers for lipid droplets with 1, 8-naphthalimide unit | |
Hovor et al. | Water-soluble norsquaraine dyes for protein labeling and pH-sensing applications | |
Zaitsev et al. | A straightforward approach to carborane-substituted BODIPY derivatives via nucleophilic aromatic substitution: Synthesis and photodynamic properties | |
Boujut et al. | Indazole versus indole-based cationic merocyanines with red shifted in-cellulo emission for selective mitochondria imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CALIFORNIA INSTITUTE OF TECHNOLOGY, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DOUGHERTY, DENNIS A.;GRUBBS, ROBERT H.;REGAN, CLINTON J.;SIGNING DATES FROM 20140909 TO 20140910;REEL/FRAME:033827/0408 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |